<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92774</article-id><article-id pub-id-type="doi">10.7554/eLife.92774</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92774.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Mutant mice lacking alternatively spliced p53 isoforms unveil <italic>Ackr4</italic> as a male-specific prognostic factor in Myc-driven B-cell lymphomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fajac</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Simeonova</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Leemput</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gabriel</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Morin</surname><given-names>Aurélie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lejour</surname><given-names>Vincent</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2797-1507</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hamon</surname><given-names>Annaïg</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rakotopare</surname><given-names>Jeanne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Vaysse-Zinkhöfer</surname><given-names>Wilhelm</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Eldawra</surname><given-names>Eliana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Pinskaya</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Morillon</surname><given-names>Antonin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0575-5264</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bourdon</surname><given-names>Jean-Christophe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4623-9386</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bardot</surname><given-names>Boris</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4976-9593</contrib-id><email>boris.bardot@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Toledo</surname><given-names>Franck</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3798-4106</contrib-id><email>Franck.Toledo@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Genetics of Tumor Suppression, Institut Curie</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS UMR3244</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne University</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013cjyk83</institution-id><institution>PSL Research University</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Non Coding RNA, Epigenetic and Genome Fluidity, Institut Curie</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/039c6rk82</institution-id><institution>School of Medicine, Ninewells Hospital, University of Dundee</institution></institution-wrap><addr-line><named-content content-type="city">Dundee</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>National Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>National Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>09</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP92774</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-10-13"><day>13</day><month>10</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-18"><day>18</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.13.562180"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-10"><day>10</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92774.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-08-27"><day>27</day><month>08</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92774.2"/></event></pub-history><permissions><copyright-statement>© 2024, Fajac et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Fajac et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92774-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92774-figures-v1.pdf"/><abstract><p>The <italic>Trp53</italic> gene encodes several isoforms of elusive biological significance. Here, we show that mice lacking the <italic>Trp53</italic> alternatively spliced (AS) exon, thereby expressing the canonical p53 protein but not isoforms with the AS C-terminus, have unexpectedly lost a male-specific protection against Myc-induced B-cell lymphomas. Lymphomagenesis was delayed in <italic>Trp53<sup>+/+</sup>Eμ-Myc</italic> males compared to <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males, but also compared to <italic>Trp53<sup>+/+</sup>Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> females. Pre-tumoral splenic cells from <italic>Trp53<sup>+/+</sup>Eμ-Myc</italic> males exhibited a higher expression of <italic>Ackr4,</italic> encoding an atypical chemokine receptor with tumor suppressive effects. We identified <italic>Ackr4</italic> as a p53 target gene whose p53-mediated transactivation is inhibited by estrogens, and as a male-specific factor of good prognosis relevant for murine <italic>Eμ-Myc</italic>-induced and human Burkitt lymphomas. Furthermore, the knockout of <italic>ACKR4</italic> increased the chemokine-guided migration of Burkitt lymphoma cells. These data demonstrate the functional relevance of alternatively spliced p53 isoforms and reveal sex disparities in Myc-driven lymphomagenesis.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Human cells divide many times during a lifetime, a process that requires careful regulation to avoid uncontrolled cell division, which can lead to various disorders, including cancer. For example, <italic>TP53</italic>, which encodes multiple proteins, is the most commonly mutated gene in cancers.</p><p><italic>TP53</italic> carries the instructions to make a tumor suppressor protein, known as p53, which can stop cancers from forming and spreading. In humans and mice, <italic>TP53</italic> (and the mouse analogue <italic>Trp53</italic>) can also be read by the cell to make several slightly different versions of the p53 protein, known as isoforms. The p53 isoforms are much less studied and their role in an organism is still unclear.</p><p>To address this, Fajac et al. used genome editing to make mouse strains that were still able to express p53, but were only able to create a specific subset of p53 isoforms. In these mice, part of the <italic>Trp53</italic> gene had been mutated to remove the cell’s ability to make isoforms with an alternative C-terminal end.</p><p>Fajac et al. then allowed these mice to breed with mice that were model organisms for a cancer called B-cell lymphoma. This revealed that male offspring that lacked alternative p53 isoforms were more susceptible to B-cell lymphoma and that they had decreased levels of the protein ACKR4, a receptor for signaling proteins that regulate cellular movement. Human datasets showed that having higher levels of ACKR4 could be linked to a better disease prognosis in male patients with Burkitt lymphoma, a rare but aggressive form of B-cell lymphoma. The same effect was not observed in females, suggesting that measuring ACKR4 gene expression in male patients with Burkitt lymphoma might be useful to identify the patients at higher risk.</p><p>The study from Fajac et al. provides a new perspective on p53 – one of the most studied proteins. It highlights specific p53 isoforms and the ACKR4 protein as a potential way to identify male patients at higher risk from a type of B-cell lymphoma.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>p53</kwd><kwd>Ackr4</kwd><kwd>Myc</kwd><kwd>Burkitt lymphoma</kwd><kwd>sex disparity in cancer</kwd><kwd>Ccl21</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004431</institution-id><institution>Fondation de France</institution></institution-wrap></funding-source><award-id>Comité tumeurs</award-id><principal-award-recipient><name><surname>Toledo</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004099</institution-id><institution>Ligue Contre le Cancer</institution></institution-wrap></funding-source><award-id>Labellisation</award-id><principal-award-recipient><name><surname>Toledo</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004099</institution-id><institution>Ligue Contre le Cancer</institution></institution-wrap></funding-source><award-id>Comité Ile de France</award-id><principal-award-recipient><name><surname>Toledo</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004097</institution-id><institution>Fondation ARC pour la Recherche sur le Cancer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Toledo</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>875532-Prostator-ERC-2019-PoC</award-id><principal-award-recipient><name><surname>Morillon</surname><given-names>Antonin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The male-specific tumor-suppressive effects of minor p53 isoforms were correlated with higher <italic>Ackr4</italic> expression levels, which have implications for sex-specific cancer prognosis in humans.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>TP53</italic>, the human gene for tumor suppressor p53, encodes several isoforms owing to distinct promoters, alternative splicing, and multiple translation initiation sites (<xref ref-type="bibr" rid="bib10">Bourdon et al., 2005</xref>; <xref ref-type="bibr" rid="bib15">Courtois et al., 2002</xref>; <xref ref-type="bibr" rid="bib21">Flaman et al., 1996</xref>; <xref ref-type="bibr" rid="bib71">Yin et al., 2002</xref>). p53 alternative isoforms can be abnormally expressed in cancer cells and some may regulate the canonical p53 protein (<xref ref-type="bibr" rid="bib4">Anbarasan and Bourdon, 2019</xref>; <xref ref-type="bibr" rid="bib10">Bourdon et al., 2005</xref>; <xref ref-type="bibr" rid="bib45">Mondal et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Senturk et al., 2014</xref>). However, aberrant RNA splicing is a common feature of cancer cells (<xref ref-type="bibr" rid="bib24">Graubert et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Martin et al., 2013</xref>; <xref ref-type="bibr" rid="bib49">Pajares et al., 2007</xref>; <xref ref-type="bibr" rid="bib55">Sette and Paronetto, 2022</xref>) and to which extent alternative splicing generates functionally relevant proteins is controversial (<xref ref-type="bibr" rid="bib1">Abascal et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Bardot and Toledo, 2015</xref>; <xref ref-type="bibr" rid="bib8">Blencowe, 2017</xref>; <xref ref-type="bibr" rid="bib64">Tress et al., 2017a</xref>; <xref ref-type="bibr" rid="bib65">Tress et al., 2017b</xref>; <xref ref-type="bibr" rid="bib66">Ule and Blencowe, 2019</xref>; <xref ref-type="bibr" rid="bib70">Weatheritt et al., 2016</xref>). Thus, the biological importance of many p53 isoforms remains elusive.</p><p>Like its human <italic>TP53</italic> homolog, the murine <italic>Trp53</italic> gene encodes multiple isoforms differing in their N- or C-termini (<xref ref-type="bibr" rid="bib5">Arai et al., 1986</xref>; <xref ref-type="bibr" rid="bib42">Marcel et al., 2011</xref>). Mouse models to evaluate the role of p53 isoforms differing in their N-terminus revealed that Δ40-p53 overexpression leads to accelerated ageing (<xref ref-type="bibr" rid="bib41">Maier et al., 2004</xref>; <xref ref-type="bibr" rid="bib61">Steffens Reinhardt et al., 2020</xref>). However, the potential role of p53 isoforms with an alternative C-terminus was not analyzed in vivo. p53 isoforms with distinct C-termini result from the splicing of two mutually exclusive final exons: exon 11, encoding the canonical ‘α’ C-terminal domain, and the alternatively spliced (AS) exon, encoding another C-terminus (<xref ref-type="bibr" rid="bib5">Arai et al., 1986</xref>). In adult mice, isoforms with the canonical C-terminus are predominant in all tissues (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Two models (<italic>Trp53<sup>Δ31</sup></italic> and <italic>Trp53<sup>ΔCTD</sup></italic>), designed to study the consequences of a loss of the canonical p53 C-terminus, exhibited signs of increased p53 activity, leading to a rapidly lethal anemia (<xref ref-type="bibr" rid="bib26">Hamard et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Simeonova et al., 2013</xref>). To determine the role of p53-AS isoforms in vivo, we created <italic>Trp53<sup>ΔAS</sup></italic>, a mouse model with a specific deletion of the AS exon (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). In mouse embryonic fibroblasts (MEFs), the <italic>Trp53<sup>ΔAS</sup></italic> allele prevented the expression of isoforms with the AS C-terminus, whereas it did not affect RNA levels for p53 isoforms with the canonical C-terminus (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). We previously used this model to show that p53-AS isoforms had no role in the anemia affecting <italic>Trp53<sup>Δ31/Δ31</sup></italic> mice (<xref ref-type="bibr" rid="bib59">Simeonova et al., 2013</xref>). However, a detailed phenotyping of <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> mice remained to be performed. The detailed phenotyping, presented here, yielded surprising information on lymphomagenesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Stress responses in WT and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> cells</title><p>We analyzed cellular stress responses in thymocytes, known to undergo a p53-dependent apoptosis upon irradiation (<xref ref-type="bibr" rid="bib39">Lowe et al., 1993</xref>), and in primary fibroblasts, known to undergo a p53-dependent cell cycle arrest in response to various stresses; for example, DNA damage caused by irradiation or doxorubicin (<xref ref-type="bibr" rid="bib33">Kastan et al., 1992</xref>), and the Nutlin-mediated inhibition of Mdm2, a negative regulator of p53 (<xref ref-type="bibr" rid="bib68">Vassilev et al., 2004</xref>). We first compared thymocytes from irradiated wild-type (WT) and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> mice. In WT thymocytes, isoforms with the AS C-terminus were five times less abundant than isoforms with the α C-terminus at the RNA level (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), and in western blots the p53-AS protein appeared as a faint band running just ahead of, and often hard to separate from, the band specific for p53-α, the canonical full-length p53 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> thymocytes, mRNA levels for α isoforms were slightly decreased, if at all (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), whereas p53-α protein levels appeared markedly decreased (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), raising the possibility that p53-AS isoforms might contribute to p53-α abundance. Nevertheless, the transactivation of classical p53 target genes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) and apoptotic response (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>) were not significantly altered by the loss of AS isoforms. Likewise, no significant difference was observed between WT and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> fibroblasts in assays for cell cycle control (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>), expression of well-known p53 target genes (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F and G</xref>), proliferation under hyperoxic conditions (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), or the growth of tumor xenografts (<xref ref-type="fig" rid="fig1">Figure 1H</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The loss of p53-AS isoforms does not alter cellular stress responses or survival to spontaneous tumors.</title><p>(<bold>A</bold>) mRNAs for p53-α and p53-AS isoforms from thymocytes of irradiated mice were quantified by RT-qPCR, and p53-α levels in <italic>Trp53<sup>+/+</sup></italic> mice were assigned a value of 1. Means ± SEM (n = 3). (<bold>B</bold>) Protein extracts from thymocytes of <italic>Trp53<sup>+/+</sup></italic> (WT) or <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> (ΔAS) irradiated mice were immunoblotted with p53 or actin antibodies. After normalization to actin, full-length (FL) p53-α levels in WT thymocytes were assigned a value of 1. (<bold>C</bold>) mRNA levels of p53 target genes in thymocytes, before or after γ-irradiation. Means ± SEM (n = 3). (<bold>D</bold>) Thymocyte apoptotic response to γ-irradiation. Means ± SEM (n = 6). (<bold>E</bold>) Cell cycle control in mouse embryonic fibroblasts (MEFs) after γ-irradiation. Asynchronous MEFs were exposed to 0–10 Gy γ-irradiation, and after 24 hr, cells were labeled with BrdU for 1 hr and analyzed by FACS. Means ± SEM from &gt;3 independent experiments with at least two independent MEF clones per genotype. (<bold>F</bold>) mRNA levels of p53 target genes in MEFs untreated or treated with 0.5 μg/ml of clastogenic doxorubicin (Doxo) or 10 μM of the Mdm2 antagonist Nutlin. Means ± SEM from &gt;3 experiments with ≥2 independent MEF clones. (<bold>G</bold>) MEFs proliferation under hyperoxic conditions. Cells were grown according to a 3T3 protocol. Each point is the mean from four independent MEF clones, the value for each clone resulting from triplicates. (<bold>H</bold>) Growth of tumor xenografts. E1A+Ras-expressing MEFs were injected into the flanks of nude mice and tumor volumes were determined after 1–25 days. Means ± SD (n = 4 per timepoint and genotype). (<bold>I</bold>) Tumor-free survival of <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> mice (n = cohort size). (<bold>J</bold>) Incidence of the indicated tumor types, determined at death after macroscopic examination and histological analysis of <italic>Trp53<sup>+/+</sup></italic> (WT) and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> (ΔAS) mice. In (<bold>A, D, E</bold>), ns = non-significant in Student’s <italic>t</italic>-test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw unedited gels and blots for <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig1-data1-v1.jpg"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Uncropped and labeled gels and blots for <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig1-data2-v1.jpg"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Description of the <italic>Trp53<sup>ΔAS</sup></italic> mouse model and analysis of <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> thymocytes and fibroblasts.</title><p>(<bold>A</bold>) Relative expression of p53 isoforms with an α or AS C-terminus in tissues of wild-type mice. RNAs were prepared from the indicated tissues of wild-type mice, then p53-AS and p53-α mRNAs were quantified by RT-qPCR. Results are expressed as mean AS/α ratios ± SD, from three independent experiments. (<bold>B</bold>) Comparative maps of the wild-type (WT) and ΔAS <italic>Trp53</italic> alleles. Left, top: the 3’ end of the WT <italic>Trp53</italic> gene is shown; black line: intron 10; boxes are for exons, with graytones for translated regions from exon 10 (light gray), exon 11 (dark gray), and exon AS (black). Left, below: the WT <italic>Trp53</italic> allele encodes proteins with two different C-termini. (4D: tetramerization domain; CTD: C-terminal domain). Right, top: the 3’ end of the <italic>Trp53<sup>ΔAS</sup></italic> allele is shown; the AS exon was deleted and replaced by a SpeI restriction site. Right, below: the <italic>Trp53<sup>ΔAS</sup></italic> allele only enables the synthesis of proteins with the ‘canonical’ α C-terminus. (<bold>C</bold>) Quantifications of p53 isoforms with an AS or an α C-terminus, in mouse embryonic fibroblasts (MEFs) of the indicated genotypes, that were either untreated, or treated for 24 hr with 0.5 μg/ml doxorubicin (Doxo) or 10 μM Nutlin. Means ± SEM from &gt;3 experiments with ≥2 independent MEF clones of each genotype are shown. ***p&lt;0.001, *p&lt;0.05, °p=0.07 by Student’s <italic>t</italic>-test. (<bold>D</bold>) Apoptotic responses of <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> thymocytes. <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> mice were irradiated and their thymocytes were recovered and analyzed by FACS after annexin V-FITC staining. A typical experiment for cells of each genotype and condition is shown. Numbers indicate % cells, apopt.: apoptotic cells. (<bold>E</bold>) Cell cycle control of <italic>Trp53<sup>-/-</sup></italic>, <italic>Trp53<sup>+/+</sup></italic>, and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> fibroblasts. Asynchronous MEFs were exposed to 0–10 Gy γ-irradiation, then after 24 hr cells were labeled with BrdU for 1 hr and analyzed by FACS. A typical experiment for cells of each genotype and condition is shown, with % of cells in G1, S, and G2/M mentioned in each panel. (<bold>F</bold>) mRNA levels of the indicated genes were quantified in MEFs of the indicated genotypes left untreated or treated for 24 hr with 0.5 μg/ml Doxo or 10 μM Nutlin-3 (Nutlin). Means ± SEM from at least three experiments with two independent MEF clones of <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> genotypes are shown. (<bold>G</bold>) mRNA levels of the indicated genes were quantified in MEFs of the indicated genotypes left untreated or treated for 24 hr with 15 μM etoposide (Eto). Means ± SEM from at least three experiments with two independent MEF clones per genotype.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Lymphomagenesis in WT and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> mice</title><p>We compared spontaneous tumor onset in WT and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> littermates for over 2 years and observed no significant difference in tumor-free survival (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). Because lymphoma is a common neoplasm in C57Bl/6J WT mice (<xref ref-type="bibr" rid="bib11">Brayton et al., 2012</xref>) and our mouse cohorts resulted from &gt;10 generations of backcrosses with C57Bl/6J mice, we searched for evidence of lymphoma in the lymph nodes and spleen, by macroscopic examination at autopsy and histological analyses. B-cell lymphomas were observed in about 30% of mice of either genotype (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). In WT mice, a higher incidence of B-cell lymphomas was observed in females, in agreement with previous observations (<xref ref-type="bibr" rid="bib11">Brayton et al., 2012</xref>). By contrast, no obvious sex-specific bias was observed for B-cell lymphomas in <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1J</xref>), raising the possibility that the loss of p53-AS isoforms affected B-cell lymphomagenesis. However, the numbers of lymphoma-bearing mice were too small to be conclusive.</p><p>We next used <italic>Eμ-Myc</italic> transgenic mice, prone to highly penetrant B-cell lymphomas (<xref ref-type="bibr" rid="bib2">Adams et al., 1985</xref>). <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice developed B-cell lymphomas (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) with similar survival curves when sexes were not considered (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Importantly, however, death was accelerated, and tumor lymph nodes were larger, in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males compared to their <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> male counterparts, whereas no difference in lymphomagenesis was noticeable between <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> and <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> female mice (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Our data (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>), together with the fact that B-cell lymphomas occur with a higher incidence in WT C57Bl/6J female mice (<xref ref-type="bibr" rid="bib11">Brayton et al., 2012</xref>), suggested that <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> male mice are more refractory to B-cell lymphomas, and that p53-AS isoforms might confer this male-specific protection against lymphomagenesis.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Male-specific acceleration of Myc-induced B-cell lymphomagenesis in mice lacking p53-AS isoforms.</title><p>(<bold>A</bold>) Tumor-free survival of <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice, classified according to sex (n = cohort size). (<bold>B</bold>) Tumor volumes upon dissection of <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice, classified according to sex. Means ± SEM from 100 lymph nodes from <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males, 96 from <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> females, 148 from <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males, and 124 from <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> females. (<bold>C</bold>) Myc mRNA and protein levels in lymph node tumors. (<bold>D</bold>) Levels of p53-α and p53-AS transcripts and p53 protein levels in lymph node tumors. (<bold>E</bold>) Transcript levels of the indicated p53 target genes. Means ± SEM (n = 6 per genotype). (<bold>F, G</bold>) Apoptosis (<bold>F</bold>) and cell proliferation (<bold>G</bold>) in tumor lymph nodes from <italic>Eμ-Myc</italic> males were determined by immunohistochemistry with antibodies against cleaved caspase-3 and ki67, respectively. Positive cells were counted and normalized to the analyzed areas. Means ± SEM (n = 6 mice per assay and genotype). In (<bold>F, G</bold>) scale bars = 50 μm. Statistical analyses with Mantel–Cox (<bold>A</bold>) and Student’s <italic>t</italic> (<bold>B–G</bold>) tests. ***p&lt;0.001, *p&lt;0.05, ns: nonsignificant.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw unedited gels and blots for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig2-data1-v1.jpg"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Raw unedited gels and blots for <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig2-data2-v1.jpg"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Uncropped and labeled gels and blots for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig2-data3-v1.jpg"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Uncropped and labeled gels and blots for <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig2-data4-v1.jpg"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Analysis of tumors from <italic>Trp53<sup>+/+</sup> Eμ-myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice.</title><p>(<bold>A</bold>) Histological analyses of <italic>Eμ-Myc</italic>-induced tumor lymph nodes. Tumor lymph nodes were analyzed by hematoxilin-eosin staining (H&amp;E), or antibodies against B220 (a B-cell-specific marker) or CD3 (a T-cell-specific marker). <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice developed similar B-cell lymphomas, characterized by massive tissue homogenization of the lymph node by B cells. Scale bars = 50 μM. (<bold>B</bold>) Tumor-free survival of <italic>Trp53<sup>+/+</sup> Eμ-myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice are similar when sexes are not considered (n = cohort size). (<bold>C</bold>) Increased tumor-free survival of <italic>Trp53<sup>+/+</sup> Eμ-myc</italic> males compared to <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males, <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> females and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> females (n = cohort size). Statistical analysis with Mantel–Cox test. (<bold>D</bold>) <italic>Trp53</italic> DNA sequencing of <italic>Trp53<sup>+/+</sup> Eμ-myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> tumors. The portion of the <italic>Trp53</italic> gene encoding the DNA Binding domain (DBD), most frequently mutated in cancers, was sequenced for 14 tumors from <italic>Trp53<sup>+/+</sup></italic> (WT) <italic>Eμ-myc</italic> males and 18 tumors from <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> (ΔAS) <italic>Eμ-myc</italic> males, and <italic>Trp53</italic> mutations were found in 3/14 and 1/18 tumors, respectively. (<bold>E</bold>) Details on the four p53 mutations identified in (<bold>D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Cause for accelerated lymphomagenesis in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males</title><p>We next aimed to determine the mechanisms underlying the accelerated lymphomagenesis in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males. Inactivating p53 mutations were not more frequent in tumors from <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males than in those from <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males, ruling out additional mutations at the <italic>Trp53</italic> locus as potential causes for accelerated lymphomagenesis in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>). We next analyzed a subset of tumors with no detectable <italic>Trp53</italic> mutation in males of both genotypes and found that Myc was expressed at similar RNA and protein levels in all tumors (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). No difference in p53-α mRNA levels was observed in tumors from both genotypes, although a decrease at the protein level was detected in most tumors from <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Nevertheless, similar transcript levels for classical p53 target genes were observed in tumor cells of both genotypes (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). To test whether a higher tumor volume in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-myc</italic> males might result from lower apoptosis and/or higher cell proliferation, we next analyzed tumors by immunohistochemistry with antibodies against cleaved caspase-3 or ki-67, respectively. Similar apoptotic and proliferation indexes were observed for both genotypes (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>). In sum, classical assays for p53 activity in tumors failed to account for differences between the two male genotypes.</p><p>The speed of lymphomagenesis in <italic>Eμ-Myc</italic> mice correlates with the extent of B-cell expansion in the first stages of B-cell differentiation (<xref ref-type="bibr" rid="bib36">Langdon et al., 1986</xref>) and p53 was proposed to control the pool of early B cells (<xref ref-type="bibr" rid="bib60">Slatter et al., 2010</xref>). Therefore, we determined the levels of the early pre-B/ immature B cells in 6-week-old mice, before any sign of tumor. We analyzed the spleen, a preferential site of B-cell expansion (<xref ref-type="bibr" rid="bib36">Langdon et al., 1986</xref>) with a relatively high AS/α isoform ratio (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Flow cytometry with a combination of markers was used to discriminate the pre-B, immature, transitional, and mature B subpopulations. As expected (<xref ref-type="bibr" rid="bib36">Langdon et al., 1986</xref>), we observed high numbers of pre-B and immature B cells in <italic>Eμ-Myc</italic> mice. In males, pre-B and immature B cells were more abundant in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> animals, while no difference was observed for transitional and mature B cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). By contrast, in the spleen of <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> 6-week-old male mice without the <italic>Eμ-Myc</italic> transgene, most B cells were mature B cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). In <italic>Eμ-Myc</italic> females, the numbers of pre-B and immature B cells were similar between genotypes, as were the numbers of transitional and mature B cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Interestingly, <italic>Trp53<sup>+/+</sup> Eμ-myc</italic> males, which develop lymphomas less rapidly, exhibited the lowest number of immature B cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), suggesting a direct correlation between the level of immature B cell expansion and the speed of lymphomagenesis. Together, these data suggested that p53-AS isoforms may not be required to control the pool of early B cells under normal conditions, but that in an <italic>Eμ-Myc</italic> context they would limit the expansion of pre-tumor early B cells, specifically in males.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The loss of p53-AS isoforms affects <italic>Ackr4</italic> expression in <italic>Eμ-Myc</italic> male mice.</title><p>(<bold>A</bold>) B-cell subpopulations in spleens of 6-week-old <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice. Means ± SEM (n = 6 per genotype). (<bold>B, C</bold>) RNAseq analysis of spleens from <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> (n = 3) and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> (n = 4) 4–6-week-old male mice. Volcano plot (<bold>B</bold>), with differentially expressed genes (DEGs) in red. Unsupervised clustering heatmap plot (<bold>C</bold>), with DEGs ranked according to mean fold changes, and protein-coding genes in bold. (<bold>D</bold>) RT-qPCR analysis of candidate DEGs from spleens of <italic>Trp53<sup>+/+</sup></italic> (p53<sup>WT</sup>) <italic>Eμ-Myc</italic> males and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> (p53<sup>ΔAS</sup>) <italic>Eμ-Myc</italic> males. Means ± SEM (n = 3–4 per genotype). (<bold>E</bold>) RT-qPCR analysis of indicated DEGs from spleens of 4–6-week-old <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males, <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males, <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> females, and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> females. Means ± SEM (n = 3–4 per sex and genotype). (<bold>F</bold>) <italic>Ackr4</italic> is transactivated by p53 in response to stress. Ackr4 mRNAs in untreated or doxorubicin-treated WT and <italic>Trp53<sup>-/-</sup></italic> mouse embryonic fibroblasts (MEFs). Data from 2 to 3 MEFs per genotype (<xref ref-type="bibr" rid="bib72">Younger et al., 2015</xref>). (<bold>G</bold>) A putative p53 response element in <italic>Ackr4</italic> intron 1. Top: map of the <italic>Ackr4</italic> gene. (boxes: exons [brown box: translated region]; black line: intron 1); middle: p53 ChIP in doxorubicin-treated MEFs according to ChIP-Atlas (SRX270554) (<xref ref-type="bibr" rid="bib48">Oki et al., 2018</xref>); bottom: p53 Response Element (p53RE) consensus sequence (R = G or A, W = A or T, Y = C or T), the putative p53RE and its mutated counterpart. (<bold>H</bold>) Luciferase assays of the candidate p53RE. A 1.5 kb fragment containing the WT or mutant p53RE was cloned upstream a luciferase reporter, then transfected into <italic>Trp53<sup>-/-</sup></italic> MEFs together with an expression plasmid for full length p53 (FL), p53-AS or the DNA-binding mutant p53<sup>R270H</sup> (RH). Means ± SEM (n = 4–6). (<bold>I</bold>) In MEFs, p53 activation leads to an increased <italic>Ackr4</italic> expression attenuated by estradiol. <italic>Ackr4</italic> and <italic>Cdkn1a</italic> mRNAs were quantified by RT-qPCR from <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> MEFs, untreated or treated with 10 μM Nutlin and/or 5 μg/ml 17-β estradiol (E2). Means ± SEM from four independent experiments. (<bold>J</bold>) Evidence for Myc binding at the <italic>Mt2</italic> promoter in B cells. ChIP-Atlas reports Myc binding to <italic>Mt2</italic> promoter sequences in primary B cells from the lymph nodes of Eμ-Myc mice (SRX353785, SRX353783) and in Eμ-Myc-induced lymphoma cells (SRX522383). Chr: chromosome. (<bold>K</bold>) Gene set enrichment analysis (GSEA). GSEA, performed in <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> (WT_Myc) and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> (p53DAS_Myc) male splenic cells, indicated an enrichment of hallmark Myc targets in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> cells. In (<bold>A, D, E, F, H, I</bold>) **p&lt;0.001, **p&lt;0.01, *p&lt;0.05, °p≤0.057, ns: nonsignificant in Student’s <italic>t</italic> or Mann–Whitney tests.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Analysis of pre-tumoral spleens.</title><p>(<bold>A</bold>) Cell sorting of B-cell subpopulations by FACS. Splenic cells were incubated with DAPI and the following antibodies: APC rat anti-mouse CD45R/B220, FITC rat anti-mouse CD43, PE rat anti-mouse IgM, and BV605 rat anti-mouse IgD. First, the B220+ CD43 cells were selected from DAPI-negative living cells, subsequently yielding four different B subpopulations based on IgM and IgD labeling: IgM-/IgD- pre-B cells (box 1), IgM low/IgD- immature B cells (box 2), IgM high/IgD- transitional B cells (box 3), and IgM+/IgD + mature B cells (box 4). Typical results with a <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> male mouse and a <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> male mouse are shown. (<bold>B</bold>) The loss of p53-AS isoforms does not impair B-cell differentiation in 6-week-old non-transgenic male mice. Means ± SEM from four mice per genotype. ns: nonsignificant by Student’s <italic>t</italic>-test. (<bold>C</bold>) Control for expression of p53-FL, p53-AS, and p53<sup>R270H</sup> in luciferase assays. As a control to luciferase experiments reported in <xref ref-type="fig" rid="fig3">Figure 3H</xref>, protein extracts from <italic>Trp53<sup>-/-</sup></italic> mouse embryonic fibroblasts (MEFs) transfected with expression plasmids for p53-FL, p53-AS, or p53<sup>R270H</sup> were immunoblotted with antibodies against p53, p21, and actin. Quantifications are relative to actin. p53-FL and p53-AS were expressed at similar levels and both transactivated p21, whereas the DNA-binding mutant p53<sup>R270H</sup> was expressed at higher amounts but failed to transactivate p21, as expected. nd: not determined.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Raw unedited gels and blots for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig3-figsupp1-data1-v1.jpg"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Uncropped and labeled gels and blots for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>.</title></caption><media mimetype="image" mime-subtype="jpeg" xlink:href="elife-92774-fig3-figsupp1-data2-v1.jpg"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Transcriptomes from <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> male spleens</title><p>We next performed bulk RNA-seq and differential expression analyses comparing the spleens from 4- to 6-week-old <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males to spleens from age-matched <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males. This revealed a limited number of significantly deregulated genes (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), including 13 protein-coding genes and 11 pseudogenes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Out of the 13 protein-coding genes, we focused on the 10 genes not encoding an immunoglobulin and analyzed the same samples by RT-qPCR (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). For 6 of the 10 genes, expression levels were too low to be quantified (<italic>Tcstv3</italic>), or differences in expression were not statistically significant (<italic>Masp2</italic>, <italic>Akr1c19</italic>, <italic>Cd300lh</italic>, <italic>Il5ra, Slc26a1</italic>). Of note, <italic>Il5ra</italic> belonged to this group, although it is regulated by p53 (<xref ref-type="bibr" rid="bib74">Zhu et al., 2022</xref>), which illustrates the difficulty to analyze subtle effects in our experiments. Taking this into account, we considered as potentially interesting the four remaining genes, exhibiting differences in mRNA levels with statistical significance (p&lt;0.05) or borderline statistical significance (p=0.057): <italic>Ackr4</italic>, less expressed in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males, and <italic>Fam132a</italic>, <italic>Mt2,</italic> and <italic>Prss50</italic>, with an increased expression in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Importantly, survival curves indicated that the Myc-induced lethality was delayed in <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males compared to <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males, <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> females, and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> females (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Thus, we quantified transcripts for <italic>Ackr4</italic>, <italic>Fam132a</italic>, <italic>Mt2,</italic> and <italic>Prss50</italic> in the spleen of 4–6-week-old <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> females, then compared mRNA levels in <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males versus the three other groups. Significantly higher expression of <italic>Ackr4</italic> and lower expression of <italic>Mt2</italic> were found in <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><p><italic>Ackr4</italic> (also known as <italic>Ccrl1</italic>) encodes the atypical chemokine receptor 4, a decoy receptor promoting the degradation of chemokines that modulate cancer cell proliferation and metastasis (<xref ref-type="bibr" rid="bib14">Chow and Luster, 2014</xref>; <xref ref-type="bibr" rid="bib43">Marcuzzi et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Müller et al., 2001</xref>). Our data suggested that <italic>Ackr4</italic> might be a gene transactivated by p53-α and/or p53-AS isoforms. Consistent with this, by extracting data from a transcriptome-wide study in MEFs (<xref ref-type="bibr" rid="bib72">Younger et al., 2015</xref>), we found evidence for a p53-dependent transactivation of <italic>Ackr4</italic> in response to doxorubicin (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Furthermore, ChIP-Atlas, the database of chromatin immunoprecipitation experiments (<xref ref-type="bibr" rid="bib48">Oki et al., 2018</xref>), indicated p53 binding to sequences within the intron 1 of <italic>Ackr4</italic> in doxorubicin-treated MEFs, and we identified a candidate p53 responsive element in this intron (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). We next used luciferase assays to show that this p53 responsive element can be bound and regulated by both p53-α and p53-AS (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Together, these data show that <italic>Ackr4</italic> is indeed a p53 target gene, although RNAseq data indicated that it is expressed at much lower levels than classical p53 targets like <italic>Cdkn1a</italic> or <italic>Mdm2</italic> in the splenic cells of <italic>Eμ-Myc</italic> mice (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Furthermore, <italic>Ackr4</italic> was shown to be regulated by Foxl2 and estrogen signaling in ovarian cells (<xref ref-type="bibr" rid="bib23">Georges et al., 2014</xref>) and 17-β estradiol was recently found to regulate <italic>ACKR4</italic> expression in meniscal cells from both sexes, albeit differentially (<xref ref-type="bibr" rid="bib34">Knewtson et al., 2020</xref>). Accordingly, we observed, in both WT and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> MEFs, that p53 activation with the Mdm2 antagonist Nutlin led to the transactivation of <italic>Ackr4,</italic> but that a concomitant treatment with 17-β estradiol markedly decreased, or completely abrogated, <italic>Ackr4</italic> transactivation (<xref ref-type="fig" rid="fig3">Figure 3I</xref>). By contrast, <italic>Cdkn1a</italic> was efficiently transactivated under both conditions in mutant and WT cells (<xref ref-type="fig" rid="fig3">Figure 3I</xref>). These data indicate that <italic>Ackr4</italic> is a p53 target gene whose p53-mediated transactivation can be inhibited by estrogens.</p><p>The <italic>Mt2</italic> gene, encoding the potentially oncogenic metallothionein-2 (<xref ref-type="bibr" rid="bib57">Si and Lang, 2018</xref>), was less expressed in <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> male pre-tumoral splenic cells, which raised the possibility of its direct or indirect repression by p53, potentially through the binding of p53 or the DREAM complex at its promoter (<xref ref-type="bibr" rid="bib18">Engeland, 2018</xref>; <xref ref-type="bibr" rid="bib50">Peuget and Selivanova, 2021</xref>). However, ChIP-Atlas reported no binding of these proteins at the <italic>Mt2</italic> promoter. Alternatively, evidence that Myc may impact on <italic>Mt2</italic> expression was obtained previously (<xref ref-type="bibr" rid="bib52">Qin et al., 2021</xref>), and ChIP-Atlas reported Myc binding at the <italic>Mt2</italic> promoter in primary B cells from lymph nodes of <italic>Eμ-Myc</italic> mice as well as <italic>Eμ-Myc</italic>-induced lymphoma cells (<xref ref-type="fig" rid="fig3">Figure 3J</xref>). This may suggest that the lower expression of <italic>Mt2</italic> in pre-tumoral splenic cells from <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) might result from a subtle difference in Myc signaling. Consistent with this, the comparison of transcriptomes of splenic cells from <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males and <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> males, when analyzed by gene set enrichment analysis (<xref ref-type="bibr" rid="bib62">Subramanian et al., 2005</xref>), revealed an enrichment of hallmark Myc target genes in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> male splenic cells (<xref ref-type="fig" rid="fig3">Figure 3K</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p></sec><sec id="s2-5"><title>Relevance of <italic>ACKR4</italic> expression in Burkitt lymphomas</title><p>Murine and human alternatively spliced p53 isoforms exhibit structural differences (<xref ref-type="bibr" rid="bib42">Marcel et al., 2011</xref>) and the ChIP-Atlas database (<xref ref-type="bibr" rid="bib48">Oki et al., 2018</xref>) does not report p53 binding to the human <italic>ACKR4</italic> intron 1. Nevertheless, we found that p53 activation in human cells also led to an increased <italic>ACKR4</italic> expression abrogated by 17-β estradiol, whereas 17-β estradiol had no significant effect on the p53-mediated transactivation of <italic>CDKN1A</italic> (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This led us to investigate the potential relevance of <italic>ACKR4</italic> expression in human B-cell lymphomas. We analyzed public databases of B-cell lymphomas patients with clinical and gene expression information. We first analyzed #GSE4475 (<xref ref-type="bibr" rid="bib30">Hummel et al., 2006</xref>), a dataset of mature aggressive B-cell lymphomas previously used to define Burkitt lymphoma-like specific transcriptomes, comprising 159 patients (91 men, 68 women) with clinical follow-up. Overall, <italic>ACKR4</italic> gene expression was not significantly different between male and female patients (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, left). However, average mRNA levels appeared higher in males when we considered the 30% patients of each sex with the highest <italic>ACKR4</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, right). Strikingly, when we compared the survival of 30% patients with the highest ACKR4 mRNA levels to the survival of the 30% patients with the lowest ACKR4 mRNA levels, high <italic>ACKR4</italic> expression correlated with a better prognosis in men, but not in women (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). By contrast, for <italic>MT2A,</italic> the human homolog of <italic>Mt2</italic>, differences in mRNA levels did not correlate with significant differences in survival for either sex (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>ACKR4</italic> is a male-specific prognostic factor in Burkitt lymphoma.</title><p>(<bold>A</bold>) In human cells, p53 activation leads to an increased <italic>ACKR4</italic> expression abrogated by estradiol. <italic>ACKR4</italic> and <italic>CDKN1A</italic> mRNAs were quantified by RT-qPCR from p53-proficient (MRC5) and p53-deficient (MRC5-SV40) human fibroblasts, untreated or treated with Nutlin and/or estradiol (E2). Means ± SEM from four independent experiments. (<bold>B, C</bold>) Analysis of lymphoma dataset #GSE4475. <italic>ACKR4</italic> gene expression was plotted for all lymphoma patients with clinical follow-up (91 men [M], 68 women [W]), classified according to sex (<bold>B</bold>, left). Gene expression (<bold>B</bold>, right) or survival curves (<bold>C</bold>) were plotted for the 30% patients (27 men, 20 women) with the highest or lowest <italic>ACKR4</italic> expression, classified according to sex. (<bold>D, E</bold>) Analysis of Burkitt lymphoma-specific dataset #phs00235. <italic>ACKR4</italic> gene expression was plotted for all patients with a Burkitt lymphoma diagnosed at age 0–17 (48 males, 29 females), classified according to sex (<bold>D</bold>, left). Gene expression (<bold>D</bold>, right) or survival curves (<bold>E</bold>) were plotted for the 30% patients (15 men, 9 women) with the highest or lowest <italic>ACKR4</italic> expression, classified according to sex. (<bold>F</bold>) The knockout of <italic>ACKR4</italic> in Burkitt lymphoma Raji cells increases their CCL21-guided migration. Chemotaxis was assayed by using Boyden chambers with bare polycarbonate membranes as previously described (<xref ref-type="bibr" rid="bib12">Calpe et al., 2011</xref>). Equal number of cells were deposited on the membrane of a transwell insert, then migration was determined by counting cells in the lower compartment, after 15 hr of culture with or without CCL21 added to the lower chamber. Statistical analyses by Student’s <italic>t</italic> or Mann–Whitney tests (<bold>A, B, D, F</bold>) and Mantel–Cox (<bold>C, E</bold>) test. ***p&lt;0.001, **p&lt;0.01, *p&lt;0.01, °p=0.054, ns: nonsignificant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Further analyses of human B-cell lymphoma or multiple myeloma datasets.</title><p>(<bold>A</bold>) <italic>MT2A</italic> gene expression is not a prognostic marker in human B-cell lymphomas. Survival curves for the 30% patients with the highest <italic>MT2A</italic> mRNA levels and the 30% patients with the lowest <italic>MT2A</italic> mRNA levels according to sex (n = cohort sizes), for patients from dataset #GSE4475. (<bold>B</bold>) <italic>ACKR4</italic> is a prognostic factor in Burkitt lymphomas but not in diffuse large B-cell lymphomas. Survival curves of patients from dataset #GSE181063, for the 30% patients with the highest <italic>ACKR4</italic> mRNA levels and the 30% patients with the lowest <italic>ACKR4</italic> mRNA levels, classified according to sex (n = cohort sizes), and diagnosed with either a diffuse large B-cell (top) or a Burkitt (bottom) lymphoma. (<bold>C</bold>) <italic>ACKR4</italic> is not a prognostic factor in Multiple Myeloma. Survival curves of patients from dataset #GSE136337, for the 30% patients with the highest <italic>ACKR4</italic> mRNA levels and the 30% patients with the lowest <italic>ACKR4</italic> mRNA levels in malignant plasma cells, classified according to sex (n = cohort sizes). Statistical analyses in all panels by Mantel–Cox test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Strategy to knockout <italic>ACKR4</italic> in Burkitt lymphoma cells.</title><p>Burkitt lymphoma cells were transfected with a PX459 vector expressing Cas9, a puromycin resistance gene and either of two guide RNAs targeting <italic>ACKR4</italic> (or no guide RNA for control), then puromycin-resistant cells were selected and recovered either as cellular pools or diluted to get one cell per five wells in a 96-well plate to isolate cellular clones. Individual clones were then expanded, and clonal cell populations were split for freezing and DNA extraction. DNA was analyzed by performing a PCR amplifying a fragment of <italic>ACKR4</italic>, then amplified products were cloned in a PGL3 plasmid for DNA sequencing. For each cellular clone, eight plasmid clones were sequenced to ensure information on both <italic>ACKR4</italic> alleles.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Characterization of <italic>ACKR4</italic> KO Burkitt lymphoma cell clones.</title><p>(<bold>A</bold>) Characterization of the <italic>ACKR4</italic> KO 4.14 clone. Left, DNA sequences of the region targeted by the guide RNA g4. Compared to the WT <italic>ACKR4</italic> DNA sequence from Burkitt lymphoma (BL) Raji control cells (center), the 4.14 clone has two mutated alleles: allele a, with a deletion of 17 nt (top) and allele b, with a deletion of 4 nt (bottom). Right, comparison of the ACKR4 proteins encoded by WT alleles from BL Raji control cells (center), or by the 4.14a (top) and 4.14b mutated alleles (bottom). The WT ACKR4 protein consists of 350 amino acids, including a DRY motif (at residues 136–138) essential for signal transduction. The protein region corresponding to the target of guide RNA g4 is indicated. Allele 4.14a encodes a putative protein with 59 N-terminal residues of ACKR4 and 34 amino acids of unrelated sequence due to the mutational frameshift. Allele 4.14b encodes a putative protein with 60 N-terminal residues of ACKR4. (<bold>B</bold>) Characterization of the <italic>ACKR4</italic> KO 5.2 clone. DNA sequences of the region targeted by the guide RNA g5 (left) and comparison of the encoded ACKR4 proteins (right), are represented as in (<bold>A</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>The knockout of <italic>ACKR4</italic> in Burkitt lymphoma Raji cells does not impact their proliferation.</title><p>Equal numbers of cells of the indicated genotypes were seeded, then cultured for 15 hr with or without CCL21 and counted. Statistical analyses by Student’s <italic>t</italic>-test. ns: nonsignificant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92774-fig4-figsupp4-v1.tif"/></fig></fig-group><p>We also analyzed dataset #GSE181063 (<xref ref-type="bibr" rid="bib35">Lacy et al., 2020</xref>), comprising mostly diffuse large B-cell lymphomas (DLBCL; 613 men, 536 women) and a few Burkitt lymphomas (65 men, 18 women). We found no difference in survival curves of DLBCL patients with low versus high <italic>ACKR4</italic> levels, neither in men nor in women. However, there was again an increased survival for Burkitt lymphoma male patients with high <italic>ACKR4</italic> expression, but not for women (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Next, we analyzed #phs000235 (<xref ref-type="bibr" rid="bib46">Morin et al., 2011</xref>), a Burkitt lymphoma-specific dataset (65 men, 37 women) comprising mostly patients diagnosed at 0–17 years of age, hence providing cohorts homogeneous for both tumor type and age of onset. Again, <italic>ACKR4</italic> was expressed at higher levels in a subset of male patients (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) and high <italic>ACKR4</italic> expression correlated with a better prognosis only in males (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Finally, we analyzed dataset #GSE136337 (<xref ref-type="bibr" rid="bib16">Danziger et al., 2020</xref>), comprising data from the malignant plasma cells of patients with multiple myeloma (260 men, 166 women), and found that <italic>ACKR4</italic> is not a prognostic factor for this cancer type (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Altogether, these analyses led us to conclude that, as in <italic>Eμ-Myc</italic> mice, <italic>ACKR4</italic> is a male-specific positive prognostic factor in Burkitt lymphoma, the archetype of MYC-driven B-cell lymphomas.</p><p>We next considered the possibility that ACKR4 might be more than a biomarker, if it acts as a suppressor of MYC-driven B-cell lymphomagenesis. In support of this hypothesis, ACKR4 scavenges the chemokine CCL21, a ligand of the chemokine receptor CCR7 (<xref ref-type="bibr" rid="bib7">Bastow et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Ulvmar et al., 2014</xref>), and the ACKR4-mediated sequestration of CCL21 may impair the CCR7 signaling cascade, which might lead to decreased MYC activity (<xref ref-type="bibr" rid="bib56">Shi et al., 2015</xref>). Consistent with this, a <italic>Ccr7</italic> deficiency was shown to delay the lymphomagenesis induced by <italic>Eμ-Myc</italic> in mice (<xref ref-type="bibr" rid="bib53">Rehm et al., 2011</xref>). In addition, Ccr7 is required for lymphoma cell lodging to secondary lymphoid organs (<xref ref-type="bibr" rid="bib53">Rehm et al., 2011</xref>) and ACKR4 expression was inversely correlated with the metastasis capacity of different types of cancer cells (<xref ref-type="bibr" rid="bib56">Shi et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Zhu et al., 2014</xref>). These data suggested that ACKR4 might regulate the behavior of Burkitt lymphoma cells. To test this hypothesis, we designed a CRISPR-Cas9 approach to perform the knockout of <italic>ACKR4</italic> in Raji cells. Raji is a Burkitt lymphoma cell line isolated from a 11-year-old male patient (<xref ref-type="bibr" rid="bib51">Pulvertaft, 1964</xref>). Although p53 is mutated in Raji cells (<xref ref-type="bibr" rid="bib17">Duthu et al., 1992</xref>), these cells overexpress MYC (<xref ref-type="bibr" rid="bib27">Hamlyn and Rabbitts, 1983</xref>) and express both ACKR4 and CCR7 (<xref ref-type="bibr" rid="bib20">Ferreira et al., 2014</xref>), suggesting that they might be suitable to evaluate the impact of ACKR4 on Burkitt lymphoma cell behavior, particularly their migratory capacities. Raji cells were transfected with a vector expressing Cas9, a puromycin resistance gene and either of two guide RNAs targeting <italic>ACKR4</italic> (or no guide RNA for control), then puromycin-resistant cells were selected and recovered as cellular pools or diluted to isolate cellular clones (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Both guide RNAs targeted sequences in <italic>ACKR4</italic> mapping upstream an encoded DRY motif essential for signal transduction (<xref ref-type="bibr" rid="bib69">Watts et al., 2013</xref>), so that Cas9-induced DNA breaks would generate knockout alleles. With this strategy, we obtained puromycin-resistant clones from Raji cells, two of which were verified to be <italic>ACKR4</italic> KO clones by DNA sequencing (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). We compared the proliferation and migration capacities of Raji control cells (transfected with the Cas9 expression vector without guide RNAs) and the two independent <italic>ACKR4</italic> KO Raji clones identified, cultured for 15 hr in medium supplemented or not with the CCL21 chemokine. Under these conditions, Raji cells of all genotypes appeared to proliferate similarly (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). Strikingly however, the KO of <italic>ACKR4</italic> led to a fourfold increase in CCL21-mediated cell migration, consistent with the hypothesis that ACKR4 may hinder MYC-driven B-cell lymphomagenesis (<xref ref-type="fig" rid="fig4">Figure 4F</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we analyzed a mouse model with a specific deletion of the AS exon of the <italic>Trp53</italic> gene. Despite a subtle phenotype, this model revealed that a male-specific protective effect against <italic>Eμ-Myc</italic>-induced B-cell lymphomas is lost in the absence of p53-AS isoforms. <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> males also appeared more prone to develop spontaneous lymphomas, suggesting that the sex-specific protective effect conferred by p53-AS isoforms might not be restricted to the <italic>Eμ-Myc</italic> model.</p><p>Our transcriptomic data from splenic cells of <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males disclosed very few differentially expressed genes and highlighted <italic>Ackr4</italic> as a male-specific positive prognostic factor in <italic>Eμ-Myc</italic>-induced lymphomas. Mechanistically, we identified <italic>Ackr4</italic>, expressed at low levels in splenic cells, as a p53 target gene that may be transactivated by p53-α and/or p53-AS according to luciferase assays. That <italic>Ackr4</italic> might be regulated by both types of p53 isoforms was expected because their DNA binding domains are identical. In fact, if one considers that p53-α isoforms appear more abundant than p53-AS isoforms in wild-type cells, and that the loss of p53-AS isoforms correlated with a decrease in p53-α levels in the thymocytes and tumor lymph nodes of mutant mice, then it seems likely that the reduced transactivation of <italic>Ackr4</italic> in the splenic cells of <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males could mainly result from decreased p53-α levels, rather than the loss of p53-AS isoforms per se. In addition, we observed that 17-β estradiol can inhibit the p53-mediated transactivation of <italic>Ackr4</italic>. Together, our data suggest that <italic>Ackr4</italic> may be regulated by p53-α, p53-AS, and estrogens, likely accounting for sex-specific and p53-status-dependent differences in gene expression.</p><p>Our analyses reveal that in both mice and humans <italic>Ackr4/ACKR4</italic> is a male-specific prognostic factor in Burkitt-like lymphomas. Furthermore, several lines of evidence suggest that Ackr4 might act as a tumor suppressor of Myc-driven B-cell lymphomas. As mentioned before, the ACKR4-mediated sequestration of CCL21 may impair the CCR7 signaling cascade, which might lead to decreased MYC activity (<xref ref-type="bibr" rid="bib56">Shi et al., 2015</xref>). In <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> male splenic cells, the observed lower expression of <italic>Mt2</italic>, known to be regulated by Myc (<xref ref-type="bibr" rid="bib52">Qin et al., 2021</xref>), and of many genes that are hallmark Myc targets (as revealed by GSEA), appear consistent with this hypothesis. In addition, Ccr7 is required for lymphoma cell lodging to secondary lymphoid organs (<xref ref-type="bibr" rid="bib53">Rehm et al., 2011</xref>) and ACKR4 expression was inversely correlated with the metastasis capacity of different types of cancer cells (<xref ref-type="bibr" rid="bib56">Shi et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Zhu et al., 2014</xref>). Consistent with this, we found that the KO of <italic>ACKR4</italic> in Raji Burkitt lymphoma cells led to a dramatic increase in CCL21-guided cell migration. Finally, Ackr4 regulates B cell differentiation (<xref ref-type="bibr" rid="bib32">Kara et al., 2018</xref>), which raises the possibility that an alteration of the p53-Ackr4 pathway in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> male splenic cells might contribute to increase the pools of pre-B and immature B cells that may be prone to lymphomagenesis. In sum, a decrease in Ackr4 expression might promote B-cell lymphomagenesis through several non-exclusive mechanisms. Importantly, ACKR4 was previously found to inhibit the growth and metastasis of breast, cervical, colorectal, hepatocellular, and nasopharyngeal cancer cells (<xref ref-type="bibr" rid="bib19">Feng et al., 2009</xref>; <xref ref-type="bibr" rid="bib29">Hou et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">Ju et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Shi et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Zhu et al., 2014</xref>), although no report mentioned any sex-specific bias for cancers occurring in both sexes. Our data provide evidence that sex-specific differences in <italic>Ackr4</italic> expression may have prognostic value. This suggests that measuring <italic>ACKR4</italic> gene expression in male patients with Burkitt lymphoma could be useful to identify the patients at higher risk, for whom specific therapeutic regimens might be required.</p><p>Interestingly, our data suggested that <italic>Mt2</italic> might be a male-specific negative prognostic factor in murine <italic>Eμ-Myc</italic>-induced lymphomas, but <italic>MT2A</italic> expression levels had no prognostic value in human lymphomas. A possible explanation for this discrepancy is suggested by the fact that <italic>Mt2</italic> is regulated by Myc. A translocation leading to MYC overexpression drives oncogenesis in all Burkitt lymphomas, but half of them exhibit additional missense MYC mutations enhancing its tumorigenicity (<xref ref-type="bibr" rid="bib13">Chakraborty et al., 2015</xref>). The transcriptional program of a WT and two lymphoma-associated Myc mutants were recently compared, and we noticed that one of the mutants led to an alteration in <italic>Mt2</italic> expression (<xref ref-type="bibr" rid="bib40">Mahani et al., 2021</xref>), which would abrogate any potential prognostic value.</p><p>Finally, a polymorphism in the <italic>MDM2</italic> gene promoter provided evidence that sex-specific hormones may affect p53 signaling and tumorigenesis (<xref ref-type="bibr" rid="bib9">Bond and Levine, 2007</xref>). More recently, a higher frequency of <italic>TP53</italic> mutations in men, together with an increased vulnerability to alterations of X-linked genes encoding p53 regulators, was proposed to explain a higher cancer incidence and death in male patients (<xref ref-type="bibr" rid="bib28">Haupt et al., 2019</xref>). Here, on the contrary, male mice and a subset of male patients were more efficiently protected against Burkitt-like lymphomas, which adds another layer of complexity to sex-specific differences in tumorigenesis. The p53 pathway thus underlies cancer sex-disparities through multiple mechanisms, which may notably include variations in p53 isoforms or Ackr4 expression.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Trp53</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">ENSMUSG00000059552</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Ackr4</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">ENSMUSG00000079355</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Mt2</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">ENSMUSG00000031762</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>ACKR4</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">ENSMUSG00000129048</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, both sexes)</td><td align="left" valign="bottom"><italic>Trp53<sup>ΔAS</sup>,</italic> C57Bl/6J</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">Simeonova et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, both sexes)</td><td align="left" valign="bottom"><italic>Eμ−Myc,</italic> C57Bl/6J</td><td align="left" valign="bottom">Jackson Labs</td><td align="left" valign="bottom">B6.Cg-Tg(IghMyc)22Bri/J</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, females)</td><td align="left" valign="bottom">CD-1 Nude<break/>CD-1</td><td align="left" valign="bottom">Charles River Labs</td><td align="left" valign="bottom">Crl:CD1-<italic>Foxn1<sup>nu</sup></italic></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>, both sexes)</td><td align="left" valign="bottom">C57Bl/6J</td><td align="left" valign="bottom">Charles River Labs</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus,</italic> both sexes)</td><td align="left" valign="bottom">WT, <italic>Trp53<sup>+/ΔAS</sup>, Trp53<sup>ΔAS/ΔAS</sup>, Trp53<sup>+/-</sup>, Trp53<sup>-/-</sup> fibroblasts</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Primary fibroblasts prepared from E13.5 days embryos</td><td align="left" valign="bottom">‘Cells and cell culture reagents’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>, male)</td><td align="left" valign="bottom">MRC5</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">MRC5 PD19 (#05072101)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>, male)</td><td align="left" valign="bottom">MRC5-SV40</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">MRC5-SV2 (#84100401)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>, female)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>, male)</td><td align="left" valign="bottom">Raji</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-86</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>, male)</td><td align="left" valign="bottom">Raji <italic>ACKR4</italic> KO</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><italic>ACKR4</italic> KO 4.14 &amp; 5.2 Raji derivatives</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (Adenoviral E1A)</td><td align="left" valign="bottom">pWZL-E1A12S</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">pWZL hygro 12S E1A (#18748)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human Ras)</td><td align="left" valign="bottom">pBabe-Hrasv12</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">pBabe-puro Ras v12 (# 1768)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p53 (rabbit polyclonal)</td><td align="left" valign="bottom">Novocastra</td><td align="left" valign="bottom">Leica NCL-p53-CM5p</td><td align="char" char="." valign="bottom">1/2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Myc (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="char" char="hyphen" valign="bottom">9E-10 sc40</td><td align="char" char="." valign="bottom">1/1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p21 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">F-5 sc6246</td><td align="char" char="." valign="bottom">1/200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Actin (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Actin-HRP sc47778</td><td align="char" char="." valign="bottom">1/5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD45R/B220 APC (rat, monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Anti-mouse CD45R/B220 APC (#561880)</td><td align="char" char="." valign="bottom">1/200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IgD (rat, monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Anti-mouse IgD BV 605 (#563003)</td><td align="char" char="." valign="bottom">1/100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD43 (rat, monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Anti-mouse CD43 FITC (#561856)</td><td align="char" char="." valign="bottom">1/200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IgM (rat, monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Anti-mouse IgM PE (#562033)</td><td align="char" char="." valign="bottom">1/50</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9(BB)–2A-Puro</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">PX459 (#48139)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53α-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AAAGGATGCCCATGCTACAGA</named-content>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53α-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCTTGGTCTTCAGGTAGCTGGAG</named-content>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53AS-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AAAGGATGCCCATGCTACAGA</named-content>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Trp53AS-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TGAAGTGATGGGAGCTAGCAGTT</named-content>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ackr4-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCACCTCTCCCAGCTTAAACA</named-content>; <xref ref-type="fig" rid="fig3">Figure 3</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ackr4-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AATAGTATTCCGCTGACTGGTTCAG</named-content>; <xref ref-type="fig" rid="fig3">Figure 3</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACKR4-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">ACTGCTCCTCTCTGCCGACTAC</named-content>; <xref ref-type="fig" rid="fig4">Figure 4</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACKR4-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCATTCATTTCATTTTCCTCAT</named-content>; <xref ref-type="fig" rid="fig4">Figure 4</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACKR4-g4</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Guide for CRISPR #4</td><td align="left" valign="bottom"><named-content content-type="sequence">TGGTAGTGGCAATTTATGCC</named-content>; <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACKR4-g5</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Guide for CRISPR #5</td><td align="left" valign="bottom"><named-content content-type="sequence">GGGCTGTTAATGCAGTTCAT</named-content>; <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CCL21</td><td align="left" valign="bottom">Preprotech</td><td align="left" valign="bottom">#300-35A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Superscript IV</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">TF #18090010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Nucleospin RNA II</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">FS #NZ74095520</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Power SYBR Green</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom"># 4367659</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Supersignal West Femto</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom"># 34096</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">AnnexinV-FITC apoptosis staining/ detection kit</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom"># Ab14085</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Truseq stranded Total RNA</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">#20020596</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Nucleofector Amaxa kit V</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom"># VCA-1003</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Doxorubicin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom"># D1515</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Etoposide</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom"># E1383</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nutlin 3a</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom"># SML-0580</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">17β-estradiol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom"># E2758</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">Beckton-Dickinson</td><td align="char" char="." valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom">v 10.10</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">featureCounts</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib37">Liao et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2 R package</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Love et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GSEA software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Subramanian et al., 2005</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PWMScan</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib3">Ambrosini et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CRISPOR</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Haeussler et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">GraphPad</td><td align="char" char="." valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom">v 5.0</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>Design and construction of the <italic>Trp53<sup>ΔAS</sup></italic> mouse model were previously described (<xref ref-type="bibr" rid="bib59">Simeonova et al., 2013</xref>). A minimum of 10 backcrosses with C57Bl/6J mice of both sexes (Charles River Laboratories) were performed before establishing the cohorts of <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> littermate mice used in this study. Mouse genotyping with multiple primer sets confirmed &gt;99% C57Bl/6J genetic background after 10 backcrosses (primer sequences available upon request). Cohorts of <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> mice were established with identical parental origin of the <italic>Eμ-Myc</italic> transgene. For all experiments, mice housing and treatment were conducted according to the Institutional Animal Care and Use Committee of the Institut Curie (approved project #03769.02).</p></sec><sec id="s4-2"><title>Cells and cell culture reagents</title><p>MEFs were isolated from 13.5 days post-coitum embryos and cultured in a 5% CO<sub>2</sub> and 3% O<sub>2</sub> incubator, in Dulbecco's Modified Eagle Medium (DMEM) GlutaMAX (Gibco), with 15% Fetal Bovine Serum (FBS) (PAN Biotech), 100 μM 2-mercaptoethanol (Millipore), 0.1 mM non-essential amino acids and penicillin/streptomycin (Gibco) for less than five passages, except for 3T3 experiments, performed in a 5% CO<sub>2</sub> incubator for nine passages. Cells were treated for 24 hr with 0.5 μg/ml doxorubicin (Sigma-Aldrich), 15 μM etoposide (Sigma-Aldrich), 10 μM Nutlin 3a (<xref ref-type="bibr" rid="bib68">Vassilev et al., 2004</xref>) (Sigma-Aldrich), and/or 5 μg/ml 17β-estradiol (Sigma-Aldrich). At least three independent experiments with at least two independent littermate MEF clones of each genotype and each sex were performed to measure DNA damage responses. For estradiol assays, four independent experiments with three independent MEF male clones of each genotype were performed. Human lung fibroblast MRC5 and its SV40-transformed derivatives were cultured in a 5% CO<sub>2</sub> and 3% O<sub>2</sub>-regulated incubator in Minimum Essential Medium (MEM) medium without Phenol Red (Gibco), completed with 10% FBS, 2 mM <sc>l</sc>-glutamine (Gibco), 1 mM pyruvate, 0.1 mM non-essential amino acids, and penicillin/streptomycin, and treated for 24 hr with 10 μM Nutlin 3a and/or 5 μg/ml 17β-estradiol (Merck). Four independent experiments were performed. Burkitt lymphoma cells (Raji or Raji <italic>ACKR4</italic> KO derivatives) were cultured in a 5% CO<sub>2</sub> incubator in RPMI GlutaMAX (Gibco) supplemented with 10% FBS, 2 mM <sc>l</sc>-glutamine, 1 mM pyruvate, 0.1 mM non-essential amino acids, 0.45% glucose (Sigma-Aldrich), and penicillin/streptomycin. In proliferation and migration assays, Raji control cells and two independent <italic>ACKR4</italic> KO derivatives were treated or not for 15 hr with 1 μg/ml CCL21 (PreproTech) then counted in triplicates. For all cell lines, cell culture supernatants were found negative for mycoplasma contamination.</p></sec><sec id="s4-3"><title>Quantitative RT-PCR</title><p>Total RNAs were extracted using nucleospin RNA II (Macherey-Nagel), reverse-transcribed using superscript IV (Invitrogen), and real-time quantitative PCRs were performed on an ABI PRISM 7500 using Power SYBR Green (Applied Biosystems) as previously described (<xref ref-type="bibr" rid="bib58">Simeonova et al., 2012</xref>). For quantification of p53 isoforms in healthy tissues, a forward primer in exon 10 and a reverse primer encompassing the boundary between exons 10 and 11 were used for p53-α amplification, whereas the same forward primer and a reverse primer located in exon AS were used for p53-AS amplification (see <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for primer sequences). To determine the AS/α mRNA ratios, expression levels were compared with a standard curve generated by serial dilutions of a plasmid containing both p53-AS and p53-α cDNAs.</p></sec><sec id="s4-4"><title>Western blots</title><p>Thymocytes were lysed in RIPA buffer (50 mM Tris–HCl pH 8, 150  mM NaCl, 5  mM EDTA, 0.5% deoxycholic acid, 0.1% SDS, 1% NP-40) with a cocktail of protease inhibitors (Roche) and 1  mM PMSF (Sigma). Whole-cell extracts were sonicated three times for 10 s and centrifuged at 13,000  r.p.m. for 30  min to remove cell debris. MEFs or B-cell lymphomas were lysed in Giordano’s buffer (50  mM Tris–HCl pH 7.4, 250  mM NaCl, 5  mM EDTA, 0.1% Triton X-100) with a cocktail of protease inhibitors (Roche) and 1 mM PMSF (Sigma). Protein lysate concentration was determined by bicinchoninic acid (BCA) assay (Thermo Scientific) and 30  μg of each lysate was fractionated by SDS–PAGE on a 4–12% polyacrylamide gel and transferred onto polyvinylidene difluoride (PVDF) membrane (Amersham). Membranes were incubated with antibodies against p53 (CM5, Novocastra), myc (9E-10, Santa Cruz), p21 (F-5, Santa Cruz), and actin (actin-HRP sc47778, Santa Cruz) and revealed with SuperSignal West femto detection reagent (Thermo Scientific).</p></sec><sec id="s4-5"><title>Apoptosis assays</title><p>Six-week-old <italic>Trp53<sup>+/+</sup></italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup></italic> male mice were whole-body irradiated with 5 Gy of γ-irradiation. Mice were sacrificed 4 hr later and thymocytes were recovered, stained with AnnexinV-FITC Apoptosis detection kit (Abcam), then analyzed by flow cytometry using FlowJo.</p></sec><sec id="s4-6"><title>Cell-cycle assays</title><p>Log-phase MEFs were irradiated at room temperature with a CS γ-irradiator at doses of 3 or 10 Gy, incubated for 24 hr, then pulse-labeled for 1 hr with 10 μM BrdU, fixed in 70% ethanol, double-stained with FITC anti BrdU and propidium iodide, and sorted by flow cytometry using a BD FACSort. Data were analyzed using FlowJo.</p></sec><sec id="s4-7"><title>Oncogene-induced tumor xenografts</title><p>MEFs with the indicated genotypes were sequentially infected with pWZL-E1A12S and pBABE-Hrasv12 viruses as previously described (<xref ref-type="bibr" rid="bib63">Toledo et al., 2006</xref>). In total, 5 × 10<sup>6</sup> E1A- and Ras- (E1A+Ras) expressing MEFs of each genotype were injected subcutaneously into the flanks of 7-week-old female athymic nude mice (at least four mice per genotype) and tumor volumes were determined 1, 8, 15, 21, and 25 days after injection. Importantly, populations of (E1A+Ras)-expressing cells were used to minimize potential differences in expression levels that could result from independent viral insertion sites.</p></sec><sec id="s4-8"><title>Cell sorting of B-cell subpopulations</title><p>Splenic cells were recovered from 6-week-old asymptomatic mice and incubated with DAPI and the following antibodies: APC rat anti-mouse CD45R/B220, FITC rat anti-mouse CD43, PE rat anti-mouse IgM, and BV605 rat anti-mouse IgD (BD Pharmingen). First, the B220+ CD43 cells were selected by flow cytometry from DAPI-negative living cells, yielding subsequently four different B subpopulations based on IgM and IgD labeling: IgM-/IgD- preB lymphocytes, IgM low/IgD- immature B lymphocytes, IgM high/IgD- transitional B lymphocytes, and IgM+/IgD+ mature B lymphocytes.</p></sec><sec id="s4-9"><title>RNA-seq analysis</title><p>Total RNA was extracted from the spleen of 4–6-week--old asymptomatic mice using nucleospin RNA II (Macherey-Nagel). The quality of RNA was checked with Bioanalyzer Agilent 2100 and RNAs with a RIN (RNA integrity number) &gt; 6 were retained for further analysis. RNA was depleted from ribosomal RNA, then converted into cDNA libraries using a TruSeq Stranded Total Library preparation kit (Illumina). Paired-end sequencing was performed on an Illumina MiSeq platform. Reads were mapped to the mouse genome version GRCm38 and counted on gene annotation gencode.vM18 with featureCounts (<xref ref-type="bibr" rid="bib37">Liao et al., 2014</xref>). Differentially expressed genes of C57Bl/6J genetic background with an adjusted p-value&lt;0.05 were identified using the DESeq2 R package (<xref ref-type="bibr" rid="bib38">Love et al., 2014</xref>). Gene set enrichment analysis was performed using the GSEA software with canonical pathway gene sets from the Mouse Molecular Signature Database (<xref ref-type="bibr" rid="bib62">Subramanian et al., 2005</xref>).</p></sec><sec id="s4-10"><title>Luciferase assays</title><p>The candidate p53 responsive element (p53 RE) in the <italic>Ackr4</italic> promoter was identified using the JASPAR database of binding profiles (<xref ref-type="bibr" rid="bib22">Fornes et al., 2020</xref>) with the position weight matrix scanner PWMscan (<xref ref-type="bibr" rid="bib3">Ambrosini et al., 2018</xref>). A 1.5 kb fragment from <italic>Ackr4</italic> intron 1, containing a WT or mutant p53 RE at its center, was cloned upstream an SV40 minimal promoter and a luciferase reporter gene in the backbone of a PGL3 plasmid (Promega). We used lipofectamine 2000 to transfect <italic>Trp53<sup>-/-</sup></italic> MEFs with 2 μg of either luciferase expression vector, 2 μg of an expression vector for p53<sup>WT</sup>, p53<sup>AS</sup> or the DNA-binding mutant p53<sup>R270H</sup>, and 30 ng of a renilla luciferase expression plasmid (pGL4.73, Promega) for normalization. Transfected cells were incubated for 24 hr, then trypsinized, resuspended in 75 μl culture medium with 7.5% FBS, and transferred into a well of an optical 96-well plate (Nunc). The dual-glo luciferase assay system (Promega) was used according to the manufacturer’s protocol to lyse the cells and read firefly and renilla luciferase signals. Results were normalized, then the average luciferase activity in cells transfected with the WT p53RE luciferase reporter and the p53<sup>R270H</sup> expression plasmid was assigned a value of 1.</p></sec><sec id="s4-11"><title>Generation of <italic>ACKR4</italic> knockout Burkitt lymphoma cells</title><p>Six guide RNAs (gRNAs) were designed to target the human <italic>ACKR4</italic> gene using the web tool CRISPOR (<xref ref-type="bibr" rid="bib25">Haeussler et al., 2016</xref>). For each gRNA, two reverse complementary oligonucleotides were designed (with added backbone sequences, including a 5′ G nucleotide for gRNA sequences without a 5′ G to improve transcription efficiency from a U6 promoter), annealed, and cloned in the Cas9 expression vector pSpCas9(BB)–2A-Puro (PX459) (Addgene). Preliminary tests for efficiency to induce cleavage in the targeted DNA regions were performed in HEK293T cells, which led to select the gRNAs #4 (5′-<named-content content-type="sequence">TGGTAGTGGCAATTTATGCC</named-content>-3′) and #5 (5′-<named-content content-type="sequence">GGGCTGTTAATGCAGTTCAT</named-content>-3′) for further experiments. Raji Burkitt lymphoma cells were transfected with a PX459 vector expressing gRNA #4 or #5 (or no gRNA for control) using Nucleofector Amaxa kit V (Lonza), and selection was carried out with 1 μg/ml puromycin for 3 weeks to obtain stably transfected cells. Clones were obtained by seeding cells at low density (1 cell/5 wells) in 96-well plates, expanded, then subdivided into two parts, half for storage in liquid nitrogen and half for <italic>ACKR4</italic> genotyping by Sanger DNA sequencing (see <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for primer sequences). For each cell clone, the <italic>ACKR4</italic> target DNA regions were amplified by PCR, PCR products were cloned in a PGL3 plasmid, and eight transformed bacteria colonies were sequenced (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). This led to identify two homozygous <italic>ACKR4</italic> KO clones, one (clone 4.14) obtained using gRNA #4 and one (clone 5.2) using gRNA #5 (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p></sec><sec id="s4-12"><title>Cell migration assay</title><p>Cell migration assays toward the chemokine CCL21 were performed with Boyden chambers essentially as described (<xref ref-type="bibr" rid="bib12">Calpe et al., 2011</xref>) by measuring transwell migration across bare polycarbonate membranes with a pore size of 5 μm (Corning). A total of 100 μl of culture medium (RPMI GlutaMAX, 10% FBS, 2 mM <sc>l</sc>-glutamine, 1 mM pyruvate, 0.1 mM non-essential amino acids, 0.45% glucose, and penicillin/streptomycin) containing 5 × 10<sup>5</sup> cells was added to a 6.5 mm diameter transwell insert, and 600 μl of culture medium with or without 1 μg/ml CCL21 were added to the lower compartment. After 15 hr at 37°C in 5% CO<sub>2</sub>, the number of migrated cells in the lower chamber was determined using a Coulter Counter.</p></sec><sec id="s4-13"><title>Statistical analyses</title><p>Student’s unpaired <italic>t</italic>-tests were used in most figures to analyze the differences between WT vs. ΔAS values. Log-rank (Mantel–Cox) tests were used to analyze Kaplan–Meier tumor-free survival curves. Analyses were performed using GraphPad Prism 5, and values of p&lt;0.05 were considered significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Initiated the project</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Resources, Initiated the project</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis, Supervision, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing, Initiated the project</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>For all experiments, mice housing and treatment were conducted according to Institutional Animal Care and Use Committee of the Institut Curie (approved project #03769.02).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Expression of <italic>Ackr4</italic>, <italic>Cdkn1a,</italic> and <italic>Mdm2</italic> in <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> male splenic cells.</title><p>Read numbers for the indicated genes, obtained by Bulk RNA-seq from the spleens of three <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> (WT_Myc) and four <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> (ΔAS_Myc) male mice.</p></caption><media xlink:href="elife-92774-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Details of the gene set enrichment analysis (GSEA) for hallmark Myc targets.</title><p>Datasets from <italic>Trp53<sup>+/+</sup> Eμ-Myc</italic> and <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> male splenic cells were analyzed by GSEA. A normalized enrichment score of 2.4965038 was found for the gene set 'Hallmark_Myc_targets_V1' in <italic>Trp53<sup>ΔAS/ΔAS</sup> Eμ-Myc</italic> males. The table provides details on the profile represented in <xref ref-type="fig" rid="fig3">Figure 3K</xref>, with scores and positions of gene set members on the rank ordered list.</p></caption><media xlink:href="elife-92774-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Oligonucleotide sequences.</title></caption><media xlink:href="elife-92774-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92774-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) under the accession code GSE209708. All other data are available within the article and its supplementary information.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Fajac</surname><given-names>A</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Gabriel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Splenocyte mRNA profiles of 4-6 weeks-old p53+/+ Em-Myc and p53DAS/DAS Em-Myc mice</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE209708">GSE209708</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Bentink</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Klapper</surname><given-names>W</given-names></name><name><surname>Wessendorf</surname><given-names>S</given-names></name><name><surname>Barth</surname><given-names>TF</given-names></name><name><surname>Bernd</surname><given-names>H</given-names></name><name><surname>Cogliatti</surname><given-names>S</given-names></name><name><surname>Dierlamm</surname><given-names>J</given-names></name><name><surname>Feller</surname><given-names>AC</given-names></name><name><surname>Hansmann</surname><given-names>M</given-names></name><name><surname>Haralambieva</surname><given-names>E</given-names></name><name><surname>Harder</surname><given-names>L</given-names></name><name><surname>Hasenclever</surname><given-names>D</given-names></name><name><surname>Kuehn</surname><given-names>M</given-names></name><name><surname>Lenze</surname><given-names>D</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Martin-Subero</surname><given-names>JI</given-names></name><name><surname>Moeller</surname><given-names>P</given-names></name><name><surname>Mueller-Hermelink</surname><given-names>H</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Parwaresch</surname><given-names>RM</given-names></name><name><surname>Pott</surname><given-names>C</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Rosolowski</surname><given-names>M</given-names></name><name><surname>Schwaenen</surname><given-names>C</given-names></name><name><surname>Stuerzenhofecker</surname><given-names>B</given-names></name><name><surname>Szczepanowski</surname><given-names>M</given-names></name><name><surname>Trautmann</surname><given-names>H</given-names></name><name><surname>Wacker</surname><given-names>H</given-names></name><name><surname>Spang</surname><given-names>R</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Truemper</surname><given-names>L</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><data-title>A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4475">GSE4475</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Care</surname><given-names>MA</given-names></name><name><surname>Barrens</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Whole genome expression profiling based on paraffin embedded tissue of a large DLBCL cohort</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE181063">GSE181063</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Danziger</surname><given-names>SA</given-names></name><name><surname>McConnell</surname><given-names>M</given-names></name><name><surname>Gockley</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>MH</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>F</given-names></name><name><surname>Reiss</surname><given-names>DJ</given-names></name><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Alapat</surname><given-names>DV</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Ashby</surname><given-names>C</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Couto</surname><given-names>SS</given-names></name><name><surname>van Rhee</surname><given-names>F</given-names></name><name><surname>Davies</surname><given-names>F</given-names></name><name><surname>Zangari</surname><given-names>M</given-names></name><name><surname>Petty</surname><given-names>N</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Dhodapkar</surname><given-names>M</given-names></name><name><surname>Copeland</surname><given-names>W</given-names></name><name><surname>Fox</surname><given-names>B</given-names></name><name><surname>Hoering</surname><given-names>A</given-names></name><name><surname>Fitch</surname><given-names>A</given-names></name><name><surname>Newhall</surname><given-names>K</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Trotter</surname><given-names>MW</given-names></name><name><surname>Hershberg</surname><given-names>RM</given-names></name><name><surname>Walker</surname><given-names>BA</given-names></name><name><surname>Dervan</surname><given-names>A</given-names></name><name><surname>Ratushny</surname><given-names>AV</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Identifying a high-risk cellular signature in the multiple myeloma bone marrow microenvironment_2</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136337">GSE136337</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>RD</given-names></name><name><surname>Mendez-Lago</surname><given-names>M</given-names></name><name><surname>Mungall</surname><given-names>AJ</given-names></name><name><surname>Goya</surname><given-names>R</given-names></name><name><surname>Mungall</surname><given-names>KL</given-names></name><name><surname>Corbett</surname><given-names>RD</given-names></name><name><surname>Johnson</surname><given-names>NA</given-names></name><name><surname>Severson</surname><given-names>TM</given-names></name><name><surname>Chiu</surname><given-names>R</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Jackman</surname><given-names>S</given-names></name><name><surname>Krzywinski</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>DW</given-names></name><name><surname>Trinh</surname><given-names>DL</given-names></name><name><surname>Tamura-Wells</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Firme</surname><given-names>MR</given-names></name><name><surname>Rogic</surname><given-names>S</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Yakovenko</surname><given-names>O</given-names></name><name><surname>Meyer</surname><given-names>IM</given-names></name><name><surname>Zhao</surname><given-names>EY</given-names></name><name><surname>Smailus</surname><given-names>D</given-names></name><name><surname>Moksa</surname><given-names>M</given-names></name><name><surname>Chittaranjan</surname><given-names>S</given-names></name><name><surname>Rimsza</surname><given-names>L</given-names></name><name><surname>Brooks-Wilson</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>JJ</given-names></name><name><surname>Ben-Neriah</surname><given-names>S</given-names></name><name><surname>Meissner</surname><given-names>B</given-names></name><name><surname>Woolcock</surname><given-names>B</given-names></name><name><surname>Boyle</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>H</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Tse</surname><given-names>K</given-names></name><name><surname>Butterfield</surname><given-names>Y</given-names></name><name><surname>Birol</surname><given-names>I</given-names></name><name><surname>Holt</surname><given-names>R</given-names></name><name><surname>Schein</surname><given-names>J</given-names></name><name><surname>Horsman</surname><given-names>DE</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>SJ</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>National Cancer Institute Cancer Genome Characterization Initiative</data-title><source>NCBI dbGaP</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000235.v21.p6">phs000235.v21.p6</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This project was supported by grants from the Comité Tumeurs of Fondation de France (to FT), the Comité Ile-de-France and Comité national (Labellisation 2014–18) of the Ligue Nationale Contre le Cancer (to FT), and the Fondation ARC pour la recherche sur le Cancer (to FT). IS, JR, and EE were PhD fellows of the Ministère de la Recherche; JL and AMorin were postdoctoral fellows of Cancéropôle Ile-de-France and Institut National du Cancer. MG was paid by European the Research Council 875532-Prostator-ERC-2019-PoC attributed to AMoril; JCB was supported by Cancer Research-UK. We thank K Fernandes for his participation in making the ΔAS mutation, and members of the Institut Curie platforms: I Grandjean, H Gautier, C Daviaud, M Garcia, M Verlhac, A Fosse, and P Bureau (animal facility); S Baulande and S Lameiras (NGS); M Huerre, A Nicolas, and R Leclere (histopathology); Z Maciorowski, A Viguier, and S Grondin (flow cytometry).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abascal</surname><given-names>F</given-names></name><name><surname>Ezkurdia</surname><given-names>I</given-names></name><name><surname>Rodriguez-Rivas</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>JM</given-names></name><name><surname>del Pozo</surname><given-names>A</given-names></name><name><surname>Vázquez</surname><given-names>J</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><name><surname>Tress</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Alternatively spliced homologous exons have ancient origins and are highly expressed at the protein level</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004325</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004325</pub-id><pub-id pub-id-type="pmid">26061177</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JM</given-names></name><name><surname>Harris</surname><given-names>AW</given-names></name><name><surname>Pinkert</surname><given-names>CA</given-names></name><name><surname>Corcoran</surname><given-names>LM</given-names></name><name><surname>Alexander</surname><given-names>WS</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name><name><surname>Brinster</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice</article-title><source>Nature</source><volume>318</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/318533a0</pub-id><pub-id pub-id-type="pmid">3906410</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname><given-names>G</given-names></name><name><surname>Groux</surname><given-names>R</given-names></name><name><surname>Bucher</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>PWMScan: A fast tool for scanning entire genomes with a position-specific weight matrix</article-title><source>Bioinformatics</source><volume>34</volume><fpage>2483</fpage><lpage>2484</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty127</pub-id><pub-id pub-id-type="pmid">29514181</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anbarasan</surname><given-names>T</given-names></name><name><surname>Bourdon</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The emerging landscape of p53 isoforms in physiology, cancer and degenerative diseases</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>E6257</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20246257</pub-id><pub-id pub-id-type="pmid">31835844</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>N</given-names></name><name><surname>Nomura</surname><given-names>D</given-names></name><name><surname>Yokota</surname><given-names>K</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Brill</surname><given-names>E</given-names></name><name><surname>Shohat</surname><given-names>O</given-names></name><name><surname>Rotter</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Immunologically distinct p53 molecules generated by alternative splicing</article-title><source>Molecular and Cellular Biology</source><volume>6</volume><fpage>3232</fpage><lpage>3239</lpage><pub-id pub-id-type="doi">10.1128/mcb.6.9.3232-3239.1986</pub-id><pub-id pub-id-type="pmid">3023970</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mdm4: Don’t judge an isoform by its mRNA levels!</article-title><source>Aging</source><volume>7</volume><fpage>744</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.18632/aging.100826</pub-id><pub-id pub-id-type="pmid">26525060</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastow</surname><given-names>CR</given-names></name><name><surname>Bunting</surname><given-names>MD</given-names></name><name><surname>Kara</surname><given-names>EE</given-names></name><name><surname>McKenzie</surname><given-names>DR</given-names></name><name><surname>Caon</surname><given-names>A</given-names></name><name><surname>Devi</surname><given-names>S</given-names></name><name><surname>Tolley</surname><given-names>L</given-names></name><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Frazer</surname><given-names>IH</given-names></name><name><surname>Harvey</surname><given-names>N</given-names></name><name><surname>Condina</surname><given-names>MR</given-names></name><name><surname>Young</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>McColl</surname><given-names>SR</given-names></name><name><surname>Comerford</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Scavenging of soluble and immobilized CCL21 by ACKR4 regulates peripheral dendritic cell emigration</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2025763118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2025763118</pub-id><pub-id pub-id-type="pmid">33875601</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The relationship between alternative splicing and proteomic complexity</article-title><source>Trends in Biochemical Sciences</source><volume>42</volume><fpage>407</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2017.04.001</pub-id><pub-id pub-id-type="pmid">28483376</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>GL</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans</article-title><source>Oncogene</source><volume>26</volume><fpage>1317</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210199</pub-id><pub-id pub-id-type="pmid">17322917</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourdon</surname><given-names>JC</given-names></name><name><surname>Fernandes</surname><given-names>K</given-names></name><name><surname>Murray-Zmijewski</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Diot</surname><given-names>A</given-names></name><name><surname>Xirodimas</surname><given-names>DP</given-names></name><name><surname>Saville</surname><given-names>MK</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>p53 isoforms can regulate p53 transcriptional activity</article-title><source>Genes &amp; Development</source><volume>19</volume><fpage>2122</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1101/gad.1339905</pub-id><pub-id pub-id-type="pmid">16131611</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brayton</surname><given-names>CF</given-names></name><name><surname>Treuting</surname><given-names>PM</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pathobiology of aging mice and GEM: Background strains and experimental design</article-title><source>Veterinary Pathology</source><volume>49</volume><fpage>85</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1177/0300985811430696</pub-id><pub-id pub-id-type="pmid">22215684</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calpe</surname><given-names>E</given-names></name><name><surname>Codony</surname><given-names>C</given-names></name><name><surname>Baptista</surname><given-names>MJ</given-names></name><name><surname>Abrisqueta</surname><given-names>P</given-names></name><name><surname>Carpio</surname><given-names>C</given-names></name><name><surname>Purroy</surname><given-names>N</given-names></name><name><surname>Bosch</surname><given-names>F</given-names></name><name><surname>Crespo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation</article-title><source>Blood</source><volume>118</volume><fpage>4401</fpage><lpage>4410</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-01-333682</pub-id><pub-id pub-id-type="pmid">21865343</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>AA</given-names></name><name><surname>Scuoppo</surname><given-names>C</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A common functional consequence of tumor-derived mutations within c-MYC</article-title><source>Oncogene</source><volume>34</volume><fpage>2406</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.186</pub-id><pub-id pub-id-type="pmid">24998853</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>MT</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chemokines in cancer</article-title><source>Cancer Immunology Research</source><volume>2</volume><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0160</pub-id><pub-id pub-id-type="pmid">25480554</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courtois</surname><given-names>S</given-names></name><name><surname>Verhaegh</surname><given-names>G</given-names></name><name><surname>North</surname><given-names>S</given-names></name><name><surname>Luciani</surname><given-names>MG</given-names></name><name><surname>Lassus</surname><given-names>P</given-names></name><name><surname>Hibner</surname><given-names>U</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53</article-title><source>Oncogene</source><volume>21</volume><fpage>6722</fpage><lpage>6728</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205874</pub-id><pub-id pub-id-type="pmid">12360399</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danziger</surname><given-names>SA</given-names></name><name><surname>McConnell</surname><given-names>M</given-names></name><name><surname>Gockley</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>MH</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>F</given-names></name><name><surname>Reiss</surname><given-names>DJ</given-names></name><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Alapat</surname><given-names>DV</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Ashby</surname><given-names>C</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Couto</surname><given-names>SS</given-names></name><name><surname>van Rhee</surname><given-names>F</given-names></name><name><surname>Davies</surname><given-names>F</given-names></name><name><surname>Zangari</surname><given-names>M</given-names></name><name><surname>Petty</surname><given-names>N</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Dhodapkar</surname><given-names>MV</given-names></name><name><surname>Copeland</surname><given-names>WB</given-names></name><name><surname>Fox</surname><given-names>B</given-names></name><name><surname>Hoering</surname><given-names>A</given-names></name><name><surname>Fitch</surname><given-names>A</given-names></name><name><surname>Newhall</surname><given-names>K</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Trotter</surname><given-names>MWB</given-names></name><name><surname>Hershberg</surname><given-names>RM</given-names></name><name><surname>Walker</surname><given-names>BA</given-names></name><name><surname>Dervan</surname><given-names>AP</given-names></name><name><surname>Ratushny</surname><given-names>AV</given-names></name><name><surname>Morgan</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the total therapy clinical trials</article-title><source>PLOS Medicine</source><volume>17</volume><elocation-id>e1003323</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1003323</pub-id><pub-id pub-id-type="pmid">33147277</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duthu</surname><given-names>A</given-names></name><name><surname>Debuire</surname><given-names>B</given-names></name><name><surname>Romano</surname><given-names>J</given-names></name><name><surname>Ehrhart</surname><given-names>JC</given-names></name><name><surname>Fiscella</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>E</given-names></name><name><surname>Appella</surname><given-names>E</given-names></name><name><surname>May</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>p53 mutations in Raji cells: Characterization and localization relative to other Burkitt’s lymphomas</article-title><source>Oncogene</source><volume>7</volume><fpage>2161</fpage><lpage>2167</lpage><pub-id pub-id-type="pmid">1437144</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engeland</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM</article-title><source>Cell Death and Differentiation</source><volume>25</volume><fpage>114</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.172</pub-id><pub-id pub-id-type="pmid">29125603</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>LY</given-names></name><name><surname>Ou</surname><given-names>ZL</given-names></name><name><surname>Wu</surname><given-names>FY</given-names></name><name><surname>Shen</surname><given-names>ZZ</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival</article-title><source>Clinical Cancer Research</source><volume>15</volume><fpage>2962</fpage><lpage>2970</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2495</pub-id><pub-id pub-id-type="pmid">19383822</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>A</given-names></name><name><surname>Robaina</surname><given-names>MC</given-names></name><name><surname>de Rezende</surname><given-names>L</given-names></name><name><surname>Severino</surname><given-names>P</given-names></name><name><surname>Klumb</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Histone deacetylase inhibitor prevents cell growth in Burkitt’s lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101</article-title><source>Annals of Hematology</source><volume>93</volume><fpage>983</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1007/s00277-014-2021-4</pub-id><pub-id pub-id-type="pmid">24577510</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaman</surname><given-names>JM</given-names></name><name><surname>Waridel</surname><given-names>F</given-names></name><name><surname>Estreicher</surname><given-names>A</given-names></name><name><surname>Vannier</surname><given-names>A</given-names></name><name><surname>Limacher</surname><given-names>JM</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name><name><surname>Iggo</surname><given-names>R</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The human tumour suppressor gene p53 is alternatively spliced in normal cells</article-title><source>Oncogene</source><volume>12</volume><fpage>813</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">8632903</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornes</surname><given-names>O</given-names></name><name><surname>Castro-Mondragon</surname><given-names>JA</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>van der Lee</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Richmond</surname><given-names>PA</given-names></name><name><surname>Modi</surname><given-names>BP</given-names></name><name><surname>Correard</surname><given-names>S</given-names></name><name><surname>Gheorghe</surname><given-names>M</given-names></name><name><surname>Baranašić</surname><given-names>D</given-names></name><name><surname>Santana-Garcia</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Chèneby</surname><given-names>J</given-names></name><name><surname>Ballester</surname><given-names>B</given-names></name><name><surname>Parcy</surname><given-names>F</given-names></name><name><surname>Sandelin</surname><given-names>A</given-names></name><name><surname>Lenhard</surname><given-names>B</given-names></name><name><surname>Wasserman</surname><given-names>WW</given-names></name><name><surname>Mathelier</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>JASPAR 2020: update of the open-access database of transcription factor binding profiles</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D87</fpage><lpage>D92</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1001</pub-id><pub-id pub-id-type="pmid">31701148</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georges</surname><given-names>A</given-names></name><name><surname>L’Hôte</surname><given-names>D</given-names></name><name><surname>Todeschini</surname><given-names>AL</given-names></name><name><surname>Auguste</surname><given-names>A</given-names></name><name><surname>Legois</surname><given-names>B</given-names></name><name><surname>Zider</surname><given-names>A</given-names></name><name><surname>Veitia</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The transcription factor FOXL2 mobilizes estrogen signaling to maintain the identity of ovarian granulosa cells</article-title><source>eLife</source><volume>3</volume><elocation-id>e04207</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.04207</pub-id><pub-id pub-id-type="pmid">25369636</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graubert</surname><given-names>TA</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Okeyo-Owuor</surname><given-names>T</given-names></name><name><surname>Lunn</surname><given-names>CL</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Krysiak</surname><given-names>K</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Koboldt</surname><given-names>DC</given-names></name><name><surname>Larson</surname><given-names>DE</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Dooling</surname><given-names>DJ</given-names></name><name><surname>Abbott</surname><given-names>RM</given-names></name><name><surname>Fulton</surname><given-names>RS</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Kalicki-Veizer</surname><given-names>J</given-names></name><name><surname>O’Laughlin</surname><given-names>M</given-names></name><name><surname>Grillot</surname><given-names>M</given-names></name><name><surname>Baty</surname><given-names>J</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Frater</surname><given-names>JL</given-names></name><name><surname>Nasim</surname><given-names>T</given-names></name><name><surname>Link</surname><given-names>DC</given-names></name><name><surname>Tomasson</surname><given-names>MH</given-names></name><name><surname>Westervelt</surname><given-names>P</given-names></name><name><surname>DiPersio</surname><given-names>JF</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Ley</surname><given-names>TJ</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Walter</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes</article-title><source>Nature Genetics</source><volume>44</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/ng.1031</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeussler</surname><given-names>M</given-names></name><name><surname>Schönig</surname><given-names>K</given-names></name><name><surname>Eckert</surname><given-names>H</given-names></name><name><surname>Eschstruth</surname><given-names>A</given-names></name><name><surname>Mianné</surname><given-names>J</given-names></name><name><surname>Renaud</surname><given-names>JB</given-names></name><name><surname>Schneider-Maunoury</surname><given-names>S</given-names></name><name><surname>Shkumatava</surname><given-names>A</given-names></name><name><surname>Teboul</surname><given-names>L</given-names></name><name><surname>Kent</surname><given-names>J</given-names></name><name><surname>Joly</surname><given-names>JS</given-names></name><name><surname>Concordet</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>148</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-1012-2</pub-id><pub-id pub-id-type="pmid">27380939</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamard</surname><given-names>PJ</given-names></name><name><surname>Barthelery</surname><given-names>N</given-names></name><name><surname>Hogstad</surname><given-names>B</given-names></name><name><surname>Mungamuri</surname><given-names>SK</given-names></name><name><surname>Tonnessen</surname><given-names>CA</given-names></name><name><surname>Carvajal</surname><given-names>LA</given-names></name><name><surname>Senturk</surname><given-names>E</given-names></name><name><surname>Gillespie</surname><given-names>V</given-names></name><name><surname>Aaronson</surname><given-names>SA</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Manfredi</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>1868</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1101/gad.224386.113</pub-id><pub-id pub-id-type="pmid">24013501</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamlyn</surname><given-names>PH</given-names></name><name><surname>Rabbitts</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Translocation joins c-myc and immunoglobulin gamma 1 genes in a Burkitt lymphoma revealing a third exon in the c-myc oncogene</article-title><source>Nature</source><volume>304</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1038/304135a0</pub-id><pub-id pub-id-type="pmid">6306472</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haupt</surname><given-names>S</given-names></name><name><surname>Caramia</surname><given-names>F</given-names></name><name><surname>Herschtal</surname><given-names>A</given-names></name><name><surname>Soussi</surname><given-names>T</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Haupt</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5385</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13266-3</pub-id><pub-id pub-id-type="pmid">31772231</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer</article-title><source>Gynecologic Oncology</source><volume>130</volume><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2013.04.015</pub-id><pub-id pub-id-type="pmid">23603371</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Bentink</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Klapper</surname><given-names>W</given-names></name><name><surname>Wessendorf</surname><given-names>S</given-names></name><name><surname>Barth</surname><given-names>TFE</given-names></name><name><surname>Bernd</surname><given-names>HW</given-names></name><name><surname>Cogliatti</surname><given-names>SB</given-names></name><name><surname>Dierlamm</surname><given-names>J</given-names></name><name><surname>Feller</surname><given-names>AC</given-names></name><name><surname>Hansmann</surname><given-names>ML</given-names></name><name><surname>Haralambieva</surname><given-names>E</given-names></name><name><surname>Harder</surname><given-names>L</given-names></name><name><surname>Hasenclever</surname><given-names>D</given-names></name><name><surname>Kühn</surname><given-names>M</given-names></name><name><surname>Lenze</surname><given-names>D</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Martin-Subero</surname><given-names>JI</given-names></name><name><surname>Möller</surname><given-names>P</given-names></name><name><surname>Müller-Hermelink</surname><given-names>HK</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Parwaresch</surname><given-names>RM</given-names></name><name><surname>Pott</surname><given-names>C</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Rosolowski</surname><given-names>M</given-names></name><name><surname>Schwaenen</surname><given-names>C</given-names></name><name><surname>Stürzenhofecker</surname><given-names>B</given-names></name><name><surname>Szczepanowski</surname><given-names>M</given-names></name><name><surname>Trautmann</surname><given-names>H</given-names></name><name><surname>Wacker</surname><given-names>HH</given-names></name><name><surname>Spang</surname><given-names>R</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Trümper</surname><given-names>L</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><collab>Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe</collab></person-group><year iso-8601-date="2006">2006</year><article-title>A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling</article-title><source>The New England Journal of Medicine</source><volume>354</volume><fpage>2419</fpage><lpage>2430</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa055351</pub-id><pub-id pub-id-type="pmid">16760442</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Loss of atypical chemokine receptor 4 facilitates C-C motif chemokine ligand 21-mediated tumor growth and invasion in nasopharyngeal carcinoma</article-title><source>Experimental and Therapeutic Medicine</source><volume>17</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.3892/etm.2018.7007</pub-id><pub-id pub-id-type="pmid">30651842</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kara</surname><given-names>EE</given-names></name><name><surname>Bastow</surname><given-names>CR</given-names></name><name><surname>McKenzie</surname><given-names>DR</given-names></name><name><surname>Gregor</surname><given-names>CE</given-names></name><name><surname>Fenix</surname><given-names>KA</given-names></name><name><surname>Babb</surname><given-names>R</given-names></name><name><surname>Norton</surname><given-names>TS</given-names></name><name><surname>Zotos</surname><given-names>D</given-names></name><name><surname>Rodda</surname><given-names>LB</given-names></name><name><surname>Hermes</surname><given-names>JR</given-names></name><name><surname>Bourne</surname><given-names>K</given-names></name><name><surname>Gilchrist</surname><given-names>DS</given-names></name><name><surname>Nibbs</surname><given-names>RJ</given-names></name><name><surname>Alsharifi</surname><given-names>M</given-names></name><name><surname>Vinuesa</surname><given-names>CG</given-names></name><name><surname>Tarlinton</surname><given-names>DM</given-names></name><name><surname>Brink</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>GR</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Comerford</surname><given-names>I</given-names></name><name><surname>McColl</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Atypical chemokine receptor 4 shapes activated B cell fate</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>801</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1084/jem.20171067</pub-id><pub-id pub-id-type="pmid">29386231</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name><name><surname>el-Deiry</surname><given-names>WS</given-names></name><name><surname>Carrier</surname><given-names>F</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>WV</given-names></name><name><surname>Plunkett</surname><given-names>BS</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Fornace</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia</article-title><source>Cell</source><volume>71</volume><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90593-2</pub-id><pub-id pub-id-type="pmid">1423616</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Knewtson</surname><given-names>KE</given-names></name><name><surname>Gonzalez Flores</surname><given-names>JG</given-names></name><name><surname>Pacicca</surname><given-names>DM</given-names></name><name><surname>Robinson</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptome Sequencing Reveals Sex Differences in Human Meniscal Cell Response to Estrogen Based on Dosing Kinetics</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.27.064451</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacy</surname><given-names>SE</given-names></name><name><surname>Barrans</surname><given-names>SL</given-names></name><name><surname>Beer</surname><given-names>PA</given-names></name><name><surname>Painter</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>AG</given-names></name><name><surname>Roman</surname><given-names>E</given-names></name><name><surname>Cooke</surname><given-names>SL</given-names></name><name><surname>Ruiz</surname><given-names>C</given-names></name><name><surname>Glover</surname><given-names>P</given-names></name><name><surname>Van Hoppe</surname><given-names>SJL</given-names></name><name><surname>Webster</surname><given-names>N</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Tooze</surname><given-names>RM</given-names></name><name><surname>Patmore</surname><given-names>R</given-names></name><name><surname>Burton</surname><given-names>C</given-names></name><name><surname>Crouch</surname><given-names>S</given-names></name><name><surname>Hodson</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report</article-title><source>Blood</source><volume>135</volume><fpage>1759</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003535</pub-id><pub-id pub-id-type="pmid">32187361</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langdon</surname><given-names>WY</given-names></name><name><surname>Harris</surname><given-names>AW</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice</article-title><source>Cell</source><volume>47</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(86)90361-2</pub-id><pub-id pub-id-type="pmid">3093082</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>SW</given-names></name><name><surname>Osborne</surname><given-names>BA</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>p53 is required for radiation-induced apoptosis in mouse thymocytes</article-title><source>Nature</source><volume>362</volume><fpage>847</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1038/362847a0</pub-id><pub-id pub-id-type="pmid">8479522</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahani</surname><given-names>A</given-names></name><name><surname>Arvidsson</surname><given-names>G</given-names></name><name><surname>Sadeghi</surname><given-names>L</given-names></name><name><surname>Grandien</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>APH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Differential transcriptional reprogramming by wild type and lymphoma-associated mutant MYC proteins as B-cells convert to a lymphoma phenotype</article-title><source>Cancers</source><volume>13</volume><elocation-id>6093</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13236093</pub-id><pub-id pub-id-type="pmid">34885204</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>B</given-names></name><name><surname>Gluba</surname><given-names>W</given-names></name><name><surname>Bernier</surname><given-names>B</given-names></name><name><surname>Turner</surname><given-names>T</given-names></name><name><surname>Mohammad</surname><given-names>K</given-names></name><name><surname>Guise</surname><given-names>T</given-names></name><name><surname>Sutherland</surname><given-names>A</given-names></name><name><surname>Thorner</surname><given-names>M</given-names></name><name><surname>Scrable</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Modulation of mammalian life span by the short isoform of p53</article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>306</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1101/gad.1162404</pub-id><pub-id pub-id-type="pmid">14871929</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcel</surname><given-names>V</given-names></name><name><surname>Dichtel-Danjoy</surname><given-names>ML</given-names></name><name><surname>Sagne</surname><given-names>C</given-names></name><name><surname>Hafsi</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Ortiz-Cuaran</surname><given-names>S</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Mollereau</surname><given-names>B</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name><name><surname>Bourdon</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Biological functions of p53 isoforms through evolution: Lessons from animal and cellular models</article-title><source>Cell Death and Differentiation</source><volume>18</volume><fpage>1815</fpage><lpage>1824</lpage><pub-id pub-id-type="doi">10.1038/cdd.2011.120</pub-id><pub-id pub-id-type="pmid">21941372</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcuzzi</surname><given-names>E</given-names></name><name><surname>Angioni</surname><given-names>R</given-names></name><name><surname>Molon</surname><given-names>B</given-names></name><name><surname>Calì</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Chemokines and chemokine receptors: Orchestrating tumor metastasization</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>E96</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20010096</pub-id><pub-id pub-id-type="pmid">30591657</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Maßhöfer</surname><given-names>L</given-names></name><name><surname>Temming</surname><given-names>P</given-names></name><name><surname>Rahmann</surname><given-names>S</given-names></name><name><surname>Metz</surname><given-names>C</given-names></name><name><surname>Bornfeld</surname><given-names>N</given-names></name><name><surname>van de Nes</surname><given-names>J</given-names></name><name><surname>Klein-Hitpass</surname><given-names>L</given-names></name><name><surname>Hinnebusch</surname><given-names>AG</given-names></name><name><surname>Horsthemke</surname><given-names>B</given-names></name><name><surname>Lohmann</surname><given-names>DR</given-names></name><name><surname>Zeschnigk</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3</article-title><source>Nature Genetics</source><volume>45</volume><fpage>933</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1038/ng.2674</pub-id><pub-id pub-id-type="pmid">23793026</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondal</surname><given-names>AM</given-names></name><name><surname>Horikawa</surname><given-names>I</given-names></name><name><surname>Pine</surname><given-names>SR</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Morgan</surname><given-names>KM</given-names></name><name><surname>Vera</surname><given-names>E</given-names></name><name><surname>Mazur</surname><given-names>SJ</given-names></name><name><surname>Appella</surname><given-names>E</given-names></name><name><surname>Vojtesek</surname><given-names>B</given-names></name><name><surname>Blasco</surname><given-names>MA</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>5247</fpage><lpage>5257</lpage><pub-id pub-id-type="doi">10.1172/JCI70355</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>RD</given-names></name><name><surname>Mendez-Lago</surname><given-names>M</given-names></name><name><surname>Mungall</surname><given-names>AJ</given-names></name><name><surname>Goya</surname><given-names>R</given-names></name><name><surname>Mungall</surname><given-names>KL</given-names></name><name><surname>Corbett</surname><given-names>RD</given-names></name><name><surname>Johnson</surname><given-names>NA</given-names></name><name><surname>Severson</surname><given-names>TM</given-names></name><name><surname>Chiu</surname><given-names>R</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Jackman</surname><given-names>S</given-names></name><name><surname>Krzywinski</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>DW</given-names></name><name><surname>Trinh</surname><given-names>DL</given-names></name><name><surname>Tamura-Wells</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Firme</surname><given-names>MR</given-names></name><name><surname>Rogic</surname><given-names>S</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Yakovenko</surname><given-names>O</given-names></name><name><surname>Meyer</surname><given-names>IM</given-names></name><name><surname>Zhao</surname><given-names>EY</given-names></name><name><surname>Smailus</surname><given-names>D</given-names></name><name><surname>Moksa</surname><given-names>M</given-names></name><name><surname>Chittaranjan</surname><given-names>S</given-names></name><name><surname>Rimsza</surname><given-names>L</given-names></name><name><surname>Brooks-Wilson</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>JJ</given-names></name><name><surname>Ben-Neriah</surname><given-names>S</given-names></name><name><surname>Meissner</surname><given-names>B</given-names></name><name><surname>Woolcock</surname><given-names>B</given-names></name><name><surname>Boyle</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>H</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Tse</surname><given-names>K</given-names></name><name><surname>Butterfield</surname><given-names>Y</given-names></name><name><surname>Birol</surname><given-names>I</given-names></name><name><surname>Holt</surname><given-names>R</given-names></name><name><surname>Schein</surname><given-names>J</given-names></name><name><surname>Horsman</surname><given-names>DE</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma</article-title><source>Nature</source><volume>476</volume><fpage>298</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/nature10351</pub-id><pub-id pub-id-type="pmid">21796119</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Homey</surname><given-names>B</given-names></name><name><surname>Soto</surname><given-names>H</given-names></name><name><surname>Ge</surname><given-names>N</given-names></name><name><surname>Catron</surname><given-names>D</given-names></name><name><surname>Buchanan</surname><given-names>ME</given-names></name><name><surname>McClanahan</surname><given-names>T</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Wagner</surname><given-names>SN</given-names></name><name><surname>Barrera</surname><given-names>JL</given-names></name><name><surname>Mohar</surname><given-names>A</given-names></name><name><surname>Verástegui</surname><given-names>E</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Involvement of chemokine receptors in breast cancer metastasis</article-title><source>Nature</source><volume>410</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/35065016</pub-id><pub-id pub-id-type="pmid">11242036</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oki</surname><given-names>S</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Shioi</surname><given-names>G</given-names></name><name><surname>Hatanaka</surname><given-names>H</given-names></name><name><surname>Ogasawara</surname><given-names>O</given-names></name><name><surname>Okuda</surname><given-names>Y</given-names></name><name><surname>Kawaji</surname><given-names>H</given-names></name><name><surname>Nakaki</surname><given-names>R</given-names></name><name><surname>Sese</surname><given-names>J</given-names></name><name><surname>Meno</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data</article-title><source>EMBO Reports</source><volume>19</volume><elocation-id>e46255</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201846255</pub-id><pub-id pub-id-type="pmid">30413482</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajares</surname><given-names>MJ</given-names></name><name><surname>Ezponda</surname><given-names>T</given-names></name><name><surname>Catena</surname><given-names>R</given-names></name><name><surname>Calvo</surname><given-names>A</given-names></name><name><surname>Pio</surname><given-names>R</given-names></name><name><surname>Montuenga</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Alternative splicing: An emerging topic in molecular and clinical oncology</article-title><source>The Lancet. Oncology</source><volume>8</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(07)70104-3</pub-id><pub-id pub-id-type="pmid">17395108</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peuget</surname><given-names>S</given-names></name><name><surname>Selivanova</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>p53-dependent repression: Dream or Reality?</article-title><source>Cancers</source><volume>13</volume><elocation-id>4850</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13194850</pub-id><pub-id pub-id-type="pmid">34638334</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulvertaft</surname><given-names>RJV</given-names></name></person-group><year iso-8601-date="1964">1964</year><article-title>Cytology of Burkitt’s tumour (African lymphoma)</article-title><source>The Lancet</source><volume>283</volume><fpage>238</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(64)92345-1</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Zeng</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Proteomic characteristics and identification of PM<sub>2.5</sub>-induced differentially expressed proteins in hepatocytes and c-Myc silenced hepatocytes</article-title><source>Ecotoxicology and Environmental Safety</source><volume>209</volume><elocation-id>111838</elocation-id><pub-id pub-id-type="doi">10.1016/j.ecoenv.2020.111838</pub-id><pub-id pub-id-type="pmid">33387776</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehm</surname><given-names>A</given-names></name><name><surname>Mensen</surname><given-names>A</given-names></name><name><surname>Schradi</surname><given-names>K</given-names></name><name><surname>Gerlach</surname><given-names>K</given-names></name><name><surname>Wittstock</surname><given-names>S</given-names></name><name><surname>Winter</surname><given-names>S</given-names></name><name><surname>Büchner</surname><given-names>G</given-names></name><name><surname>Dörken</surname><given-names>B</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Höpken</surname><given-names>UE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs</article-title><source>Blood</source><volume>118</volume><fpage>1020</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-11-321265</pub-id><pub-id pub-id-type="pmid">21586747</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senturk</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Camiolo</surname><given-names>M</given-names></name><name><surname>Stiles</surname><given-names>B</given-names></name><name><surname>Rathod</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>AM</given-names></name><name><surname>Nemajerova</surname><given-names>A</given-names></name><name><surname>Lazzara</surname><given-names>MJ</given-names></name><name><surname>Altorki</surname><given-names>NK</given-names></name><name><surname>Krainer</surname><given-names>A</given-names></name><name><surname>Moll</surname><given-names>UM</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state</article-title><source>PNAS</source><volume>111</volume><fpage>E3287</fpage><lpage>E3296</lpage><pub-id pub-id-type="doi">10.1073/pnas.1321640111</pub-id><pub-id pub-id-type="pmid">25074920</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sette</surname><given-names>C</given-names></name><name><surname>Paronetto</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Somatic mutations in core spliceosome components promote tumorigenesis and generate an exploitable vulnerability in human cancer</article-title><source>Cancers</source><volume>14</volume><elocation-id>1827</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14071827</pub-id><pub-id pub-id-type="pmid">35406598</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>LX</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Shi</surname><given-names>GM</given-names></name><name><surname>Ding</surname><given-names>ZB</given-names></name><name><surname>Ke</surname><given-names>AW</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>SJ</given-names></name><name><surname>Tang</surname><given-names>QQ</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma</article-title><source>The Journal of Pathology</source><volume>235</volume><fpage>546</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1002/path.4450</pub-id><pub-id pub-id-type="pmid">25255875</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The roles of metallothioneins in carcinogenesis</article-title><source>Journal of Hematology &amp; Oncology</source><volume>11</volume><elocation-id>107</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-018-0645-x</pub-id><pub-id pub-id-type="pmid">30139373</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Bouarich-Bourimi</surname><given-names>R</given-names></name><name><surname>Morin</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Charbonnier</surname><given-names>L</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002731</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002731</pub-id><pub-id pub-id-type="pmid">22761580</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Draskovic</surname><given-names>I</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Bouarich-Bourimi</surname><given-names>R</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Charbonnier</surname><given-names>L</given-names></name><name><surname>Soudais</surname><given-names>C</given-names></name><name><surname>Bourdon</surname><given-names>JC</given-names></name><name><surname>Huerre</surname><given-names>M</given-names></name><name><surname>Londono-Vallejo</surname><given-names>A</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutant mice lacking the p53 C-terminal domain model telomere syndromes</article-title><source>Cell Reports</source><volume>3</volume><fpage>2046</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.05.028</pub-id><pub-id pub-id-type="pmid">23770245</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slatter</surname><given-names>TL</given-names></name><name><surname>Ganesan</surname><given-names>P</given-names></name><name><surname>Holzhauer</surname><given-names>C</given-names></name><name><surname>Mehta</surname><given-names>R</given-names></name><name><surname>Rubio</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Royds</surname><given-names>JA</given-names></name><name><surname>Baird</surname><given-names>MA</given-names></name><name><surname>Braithwaite</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors</article-title><source>Cell Death and Differentiation</source><volume>17</volume><fpage>540</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/cdd.2009.136</pub-id><pub-id pub-id-type="pmid">19779492</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffens Reinhardt</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wawruszak</surname><given-names>A</given-names></name><name><surname>Groen</surname><given-names>K</given-names></name><name><surname>De Iuliis</surname><given-names>GN</given-names></name><name><surname>Avery-Kiejda</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Good cop, bad cop: Defining the roles of Δ40p53 in cancer and aging</article-title><source>Cancers</source><volume>12</volume><elocation-id>1659</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12061659</pub-id><pub-id pub-id-type="pmid">32585821</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Krummel</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>CW</given-names></name><name><surname>Rodewald</surname><given-names>LW</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Wahl</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network</article-title><source>Cancer Cell</source><volume>9</volume><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.03.014</pub-id><pub-id pub-id-type="pmid">16616333</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tress</surname><given-names>ML</given-names></name><name><surname>Abascal</surname><given-names>F</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Alternative splicing may not be the key to proteome complexity</article-title><source>Trends in Biochemical Sciences</source><volume>42</volume><fpage>98</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2016.08.008</pub-id><pub-id pub-id-type="pmid">27712956</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tress</surname><given-names>ML</given-names></name><name><surname>Abascal</surname><given-names>F</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Most alternative isoforms are not functionally important</article-title><source>Trends in Biochemical Sciences</source><volume>42</volume><fpage>408</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2017.04.002</pub-id><pub-id pub-id-type="pmid">28483377</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ule</surname><given-names>J</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Alternative splicing regulatory networks: Functions, mechanisms, and evolution</article-title><source>Molecular Cell</source><volume>76</volume><fpage>329</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.09.017</pub-id><pub-id pub-id-type="pmid">31626751</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulvmar</surname><given-names>MH</given-names></name><name><surname>Werth</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>A</given-names></name><name><surname>Kelay</surname><given-names>P</given-names></name><name><surname>Hub</surname><given-names>E</given-names></name><name><surname>Eller</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Lucas</surname><given-names>B</given-names></name><name><surname>Novitzky-Basso</surname><given-names>I</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Rülicke</surname><given-names>T</given-names></name><name><surname>Nibbs</surname><given-names>RJB</given-names></name><name><surname>Worbs</surname><given-names>T</given-names></name><name><surname>Förster</surname><given-names>R</given-names></name><name><surname>Rot</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The atypical chemokine receptor CCRL1 shapes functional CCL21 gradients in lymph nodes</article-title><source>Nature Immunology</source><volume>15</volume><fpage>623</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/ni.2889</pub-id><pub-id pub-id-type="pmid">24813163</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassilev</surname><given-names>LT</given-names></name><name><surname>Vu</surname><given-names>BT</given-names></name><name><surname>Graves</surname><given-names>B</given-names></name><name><surname>Carvajal</surname><given-names>D</given-names></name><name><surname>Podlaski</surname><given-names>F</given-names></name><name><surname>Filipovic</surname><given-names>Z</given-names></name><name><surname>Kong</surname><given-names>N</given-names></name><name><surname>Kammlott</surname><given-names>U</given-names></name><name><surname>Lukacs</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Fotouhi</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>In vivo activation of the p53 pathway by small-molecule antagonists of MDM2</article-title><source>Science</source><volume>303</volume><fpage>844</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1126/science.1092472</pub-id><pub-id pub-id-type="pmid">14704432</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>AO</given-names></name><name><surname>Verkaar</surname><given-names>F</given-names></name><name><surname>van der Lee</surname><given-names>MMC</given-names></name><name><surname>Timmerman</surname><given-names>CAW</given-names></name><name><surname>Kuijer</surname><given-names>M</given-names></name><name><surname>van Offenbeek</surname><given-names>J</given-names></name><name><surname>van Lith</surname><given-names>LHCJ</given-names></name><name><surname>Smit</surname><given-names>MJ</given-names></name><name><surname>Leurs</surname><given-names>R</given-names></name><name><surname>Zaman</surname><given-names>GJR</given-names></name><name><surname>Vischer</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>β-Arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>7169</fpage><lpage>7181</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.406108</pub-id><pub-id pub-id-type="pmid">23341447</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weatheritt</surname><given-names>RJ</given-names></name><name><surname>Sterne-Weiler</surname><given-names>T</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The ribosome-engaged landscape of alternative splicing</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>23</volume><fpage>1117</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3317</pub-id><pub-id pub-id-type="pmid">27820807</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Stephen</surname><given-names>CW</given-names></name><name><surname>Luciani</surname><given-names>MG</given-names></name><name><surname>Fåhraeus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products</article-title><source>Nature Cell Biology</source><volume>4</volume><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1038/ncb801</pub-id><pub-id pub-id-type="pmid">12032546</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younger</surname><given-names>ST</given-names></name><name><surname>Kenzelmann-Broz</surname><given-names>D</given-names></name><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Attardi</surname><given-names>LD</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrative genomic analysis reveals widespread enhancer regulation by p53 in response to DNA damage</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>4447</fpage><lpage>4462</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv284</pub-id><pub-id pub-id-type="pmid">25883152</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CCX-CKR expression in colorectal cancer and patient survival</article-title><source>The International Journal of Biological Markers</source><volume>29</volume><fpage>e40</fpage><lpage>e48</lpage><pub-id pub-id-type="doi">10.5301/jbm.5000057</pub-id><pub-id pub-id-type="pmid">24338720</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>JMJD2C mediates the MDM2/p53/IL5RA axis to promote CDDP resistance in uveal melanoma</article-title><source>Cell Death Discovery</source><volume>8</volume><elocation-id>227</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-022-00949-y</pub-id><pub-id pub-id-type="pmid">35468881</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92774.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dalal</surname><given-names>Yamini</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>National Cancer Institute</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study using engineered mouse models provides a first and <bold>compelling</bold> demonstration of a pathogenic phenotype associated with lack of expression of p53AS, an isoform of the p53 protein with a different C-terminus than canonical p53. The role of this isoform has been elusive so far and this first demonstration represents a substantial advance in our understanding of the complex role(s) of p53 isoforms. The revised article adequately addresses previous concerns.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92774.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors originally investigated the function of p53 isoforms with an alternative C-terminus encoded by the Alternatively Spliced (AS) exon in place of exon 11 encoding the canonical &quot;α&quot; C-terminal domain. For this purpose, the authors create a mouse model with a specific deletion of the AS exon.</p><p>Strengths:</p><p>Interestingly, wt or p53ΔAS/ΔAS mouse embryonic fibroblasts did not differ in cell cycle control, expression of well-known p53 target genes, proliferation under hyperoxic conditions, or the growth of tumor xenografts. However, p53-AS isoforms were shown to confer male-specific protection against lymphomagenesis in Eμ-Myc transgenic mice, prone to highly penetrant B-cell lymphomas. In fact, p53ΔAS/ΔAS Eμ-Myc mice were less protected from developing B-cell lymphomas compared to WT counterparts. The important difference that the authors find between WT and p53ΔAS/ΔAS Eμ-Myc males is a higher number of immature B cells in p53ΔAS/ΔAS vs WT mice. Higher expression of Ackr4 and lower expression of Mt2 was found in p53+/+ Eμ-Myc males compared to p53ΔAS/ΔAS counterparts, suggesting that these two transcripts are in part regulators of B-cell lymphomagenesis and enrichment for immature B cells.</p><p>The manuscript integrates an elegant genetic approach with in vivo analyses providing a robust set of data which strengthens the role of p53 isoforms in leukemogenesis.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92774.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript provides a detailed analysis of B-cell lymphomagenesis in mice lacking an alternative exon in region encoding the C-terminal (regulatory) domain of the p53 protein and thus enable to assemble the so-called p53AS isoform. This isoform differs from canonical p53 by the replacement of roughly 30 c-terminal residues by about 10 residues encoded by the alternative exon. There is biochemical and biological evidence that p53AS retains strong transcriptional and somewhat enhanced suppressive activities, with mouse models expressing protein constructs similar to p53AS showing signs of increased p53 activity leading to rapid and lethal anemia. However, the precise role of the alternative p53AS variant has not been addressed so far in a mouse model aimed at demonstrating whether the lack of this particular p53 isoform (trp53ΔAS/ΔAS mice) may cause a specific pathological phenotype.</p><p>Results show that lack of AS expression does not noticeably affect p53 the patterns of protein expression and transcriptional activity but reveals a subtle pathogenic phenotype, with trp53ΔAS/ΔAS males, but not females, tending to develop more frequently and earlier B-cell lymphoma than WT. Next, the authors then introduced ΔAS in transgenic Eμ-Myc mice that show accelerated lymphomagenesis. They show that lack of AS caused increased lethality and larger tumor lymph nodes in p53ΔAS Eμ-Myc males compared to their p53WT Eμ-Myc male counterparts, but not in females. Comparative transcriptomics identified a small set of candidate, differentially expressed gene, including Ackr4 (atypical chemokine receptor 4), which was significantly expressed in the spleens of ΔAS compared to WT controls. Ackr4 encodes a dummy receptor acting as an interceptor for multiple chemokines and thus may negatively regulate a chemokine/cytokine signalling axis involved in lymphomagenesis, which is down-regulated by estrogen signalling. Using in vitro cell models, the authors provide evidence that Ackr4 is a transcriptional target for p53 and that its p53-dependent activation is repressed by 17b-oestradiol. Finally, seeking evidence for a relevance for this gene in human lymphomagenesis, the authors analyse Burkitt lymphoma transcriptomic datasets and show that high ACKR4 expression correlated with better survival in males, but not in females</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92774.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fajac</surname><given-names>Anne</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Simeonova</surname><given-names>Iva</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Leemput</surname><given-names>Julia</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Gabriel</surname><given-names>Marc</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Morin</surname><given-names>Aurélie</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Lejour</surname><given-names>Vincent</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Hamon</surname><given-names>Annaïg</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Rakotopare</surname><given-names>Jeanne</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Vaysse-Zinkhöfer</surname><given-names>Wilhelm</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Eldawra</surname><given-names>Eliana</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Pinskaya</surname><given-names>Marina</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Morillon</surname><given-names>Antonin</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Bourdon</surname><given-names>Jean-Christophe</given-names></name><role specific-use="author">Author</role><aff><institution>University of Dundee</institution><addr-line><named-content content-type="city">Dundee</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Bardot</surname><given-names>Boris</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Toledo</surname><given-names>Franck</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>(1) In the first paragraph of the result section it is not clear why the authors introduce the function of p53ΔAS/ΔAS in thymocyte and then they mention fibroblasts. The authors should clarify this point. The authors should also explain based on what rationale they use doxorubicin and nutlin to analyze p53 activity (Figure 1 and figure S1).</p></disp-quote><p>We thank the reviewer for this comment. In the revised manuscript, we corrected this by mentioning, at the beginning of the Results section: “We analyzed cellular stress responses in thymocytes, known to undergo a p53-dependent apoptosis upon irradiation (Lowe et al., 1993), and in primary fibroblasts, known to undergo a p53-dependent cell cycle arrest in response to various stresses - e.g. DNA damage caused by irradiation or doxorubicin (Kastan et al., 1992), and the Nutlin-mediated inhibition of Mdm2, a negative regulator of p53 (Vassilev et al., 2004).”</p><disp-quote content-type="editor-comment"><p>(2) The authors should provide quantification for the western blot in figure 2D because the reduction of p53 protein level in mutant vs wt tumors is not striking.</p></disp-quote><p>In the previous version of the manuscript, the quantification of p53 bands had been included, but quantification results were mentioned below the actin bands, rather than the p53 bands, and this was probably confusing. We have corrected this in the revised version of the manuscript. The quantification results are now provided just below the p53 bands in Figs. 1B and 2D, which should clarify this point. For Figure 2D, the quantifications show a strong decrease in p53 levels for 3 out of 4 analyzed mutant tumors. For consistency purposes, in the revised manuscript the quantification results also appear below Myc bands in Fig. 2C.</p><disp-quote content-type="editor-comment"><p>(3) In the discussion section, the authors propose that a difference in Ackr4 expression may have prognostic value and that measuring ACKR4 gene expression in male patients with Burkitt lymphoma could be useful to identify the patients at higher risk. However the authors perform a lot of correlative analysis, both in mice and in patients, but the manuscript lacks of functional experiments that could help to functionally characterize Ackr4 and Mt2 in the etiology of B-cell lymphomas in males (both in mouse and in human models).</p></disp-quote><p>In the previous version of the manuscript, we proposed that Ackr4 might act as a suppressor of B-cell lymphomagenesis by attenuating Myc signaling. This hypothesis relied on studies showing that Ackr4 impairs the Ccr7 signaling cascade, which may lead to decreased Myc activity (Ulvmar et al., 2014; Shi et al., 2015; Bastow et al., 2021) and that the loss of Ccr7 may delay Myc-driven lymphomagenesis (Rehm et al., 2011). Furthermore, we proposed that the increased expression of Mt2 in p53ΔAS/ΔAS Em-Myc male splenic cells reflected an increase in Myc activity, because Mt2 is known to be regulated by Myc (Qin et al., 2021) and because the Mt2 promoter is bound by Myc in B cells according to experiments reported in the ChIP-Atlas database. However, in the first version of the manuscript this hypothesis might have appeared only partially supported by our data because an increase in Myc activity could be expected to have a more general impact, i.e. an impact not only on the expression of Mt2, but also on the expression of many canonical Myc target genes. In the revised manuscript, we show that this is indeed the case. We performed a gene set enrichment analysis (GSEA) comparing the RNAseq data from p53ΔAS/ΔAS Eμ-Myc and p53+/+ Eμ-Myc male splenic cells and found an enrichment of hallmark Myc targets in p53ΔAS/ΔAS Eμ-Myc cells. These new data, which strengthen our hypothesis of differences in Myc signaling intensity, are presented in Fig. 3K and Table S2.</p><p>Importantly, we now go beyond correlative analyses by providing direct experimental evidence that ACKR4 impacts on the behavior of Burkitt lymphoma cells. We used a CRISPR-Cas9 approach to knock-out ACKR4 in Raji Burkitt lymphoma cells and found that ACKR4 KO cells exhibited a 4-fold increase in chemokine-guided cell migration. These new data are presented in Figure 4F and the supplemental Figures S5-S7.</p><p>Finally, following a suggestion of Reviewer#2, we now also point out that “Ackr4 regulates B cell differentiation (Kara et al., 2018), which raises the possibility that an altered p53-Ackr4 pathway in p53ΔAS/ΔAS Eμ-Myc male splenic cells might contribute to increase the pools of pre-B and immature B cells that may be prone to lymphomagenesis.”</p><p>In sum, we now mention in the Discussion that a decrease in Ackr4 expression might promote B-cell lymphomagenesis through three non-exclusive mechanisms.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>(1) A great addition would be to demonstrate how p53AS specifically contributes to the regulation of Ackr4. In particular, is there evidence that p53AS might be preferentially recruited on p53 RE within that gene as compared to WT? The availability of specific antibodies that distinguish between AS and WT p53 might help to address this (experimentally complex) question. As a note, usage of such antibodies would also strengthen Fig 1B, in which the AS isoform appears as a mere faint shadow under p53, thus making its &quot;disappearance&quot; in trp53ΔAS/ΔAS difficult to evaluate.</p></disp-quote><p>We agree with the referee that efficient antibodies against p53-AS isoforms would have been useful. In fact, we tried a non-commercial antibody developed for that purpose, but it led to many unspecific bands in western blots and appeared not reliable. Importantly however, our luciferase assays clearly show that both p53-a and p53-AS can transactivate Ackr4, a result that might be expected because these isoforms share the same DNA binding domain. Furthermore, because p53-a isoforms appear more abundant than p53-AS isoforms at the protein and RNA levels (Figs. 1B and S1A), and because the loss of p53-AS isoforms leads to a significant decrease in p53-a protein levels (Figs. 1B and 2D), we think that in p53ΔAS/ΔAS cells the reduction in p53-a levels might be the main reason for a decreased transactivation of Ackr4. This is now more clearly discussed in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(2) A most interesting observation is in Fig3 A and Fig S3, showing that spleen cells of p53ΔAS Eμ-Myc males (but not females) were enriched in pre-B and immature B cells as compared to WT counterparts. This observation points to a possible defect in B cell maturation process. It would be most interesting to determine whether this particular defect is directly mediated by a p53AS-Ackr4 axis. The hypothesis raised by the authors in the Discussion section is that increased Ackr4 expression may delay lymphomatogenesis, but data in Fig 3A and 3S actually suggest that ΔAS increases the pool of immature B-cell that may be prone to lymphomagenesis.</p></disp-quote><p>We thank the reviewer for this useful comment, which we integrated in the Discussion of the revised manuscript. Ackr4 was shown to regulate B cell differentiation (Kara at al. (2018) J Exp Med 215, 801–813), so this is indeed one of the possible mechanisms by which a deregulation of the p53-Ackr4 axis might promote lymphomagenesis. We now mention: “Ackr4 regulates B cell differentiation (Kara et al., 2018), which raises the possibility that an altered p53-Ackr4 pathway in p53ΔAS/ΔAS Eμ-Myc male splenic cells might contribute to increase the pools of pre-B and immature B cells that may be prone to lymphomagenesis.” This is presented as one of three possible mechanisms by which decreased Ackr4 levels may promote tumorigenesis, the two others being the impact of Ackr4 on the chemokine-guided migration of lymphoma cells and its apparent effect on Myc signalling.</p><disp-quote content-type="editor-comment"><p>(3) The concordance with a male-specific prognostic effect of Ackr4 is most interesting in itself but is only of correlative evidence with respect to the study. Is there any information on whether p53AS expression is also a prognostic factor in BL? And is there evidence that Ackr4 may also be a male-specific prognostic factor in other B-cell malignancies, e.g. Multiple Myeloma?</p></disp-quote><p>We have now performed the CRISPR-mediated knock-out of ACKR4 in Burkitt lymphoma cells and found that it leads to a dramatic increase in chemokine-guided cell migration, which goes beyond correlation. This significant new result is mentioned in the revised abstract and presented in detail in Figures 4F and S5-S7.</p><p>Regarding p53-AS isoforms, they are murine-specific isoforms (Marcel et al. (2011) Cell Death Diff 18, 1815-1824), so there is no information on p53-AS expression in Burkitt lymphoma. Human p53 isoforms with alternative C-terminal domains are p53b and p53g isoforms, but the datasets we analyzed did not provide any information on the relative levels of p53a (the canonical isoform), p53b or p53g isoforms. We agree with the referee that this is an interesting question, but that cannot be answered with currently available datasets.</p><p>Regarding the different types of B-cell malignancies, we had already shown that Ackr4 is a male-specific prognostic factor in Burkitt lymphomas but not in Diffuse Large B cell lymphomas, which indicated that it is not a prognostic factor in all types of B cell lymphomas. For this revision, we also searched for its potential prognostic value in multiple myeloma, and found that, as for DLBCL, it is not a prognostic factor in this cancer type. This new analysis is presented in Figure S4C.</p></body></sub-article></article>